data_2mfm_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2mfm _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 2' ' ' PHE . . . . . 0.487 ' HB3' ' OG1' ' A' ' 5' ' ' THR . 98.8 m-85 . . . . . 0 N--CA 1.454 -0.266 0 CA-C-O 121.223 0.535 . . . . 3.8100000000000001 109.928 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 51.4 mtm180 . . . . . 0 C--N 1.323 -0.558 0 CA-C-N 115.417 -0.81 . . . . 5.29 112.574 -175.434 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' THR . . . . . 0.487 ' OG1' ' HB3' ' A' ' 2' ' ' PHE . 14.6 m . . . . . 0 N--CA 1.449 -0.479 0 N-CA-C 109.777 -0.453 . . . . 2.23 109.777 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . 56.36 69.26 1.86 Allowed Pre-proline 0 C--N 1.331 -0.21 0 CA-C-N 115.391 -0.822 . . . . 1.49 109.608 -171.592 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 14.6 Cg_endo -55.99 93.85 0.05 OUTLIER 'Trans proline' 0 C--N 1.348 0.53 0 C-N-CA 123.325 2.683 . . . . 2.4199999999999999 113.339 -173.261 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -98.59 -139.97 11.15 Favored Glycine 0 N--CA 1.446 -0.651 0 C-N-CA 120.769 -0.729 . . . . 1.77 112.74 179.081 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' HIS . . . . . 0.582 ' O ' ' HA ' ' A' ' 13' ' ' VAL . 74.9 t60 -70.25 -43.35 70.71 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 111.594 0.22 . . . . 5.0899999999999999 111.594 -173.695 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 18.0 m . . . . . 0 C--N 1.322 -0.595 0 N-CA-C 112.027 0.381 . . . . 4.0300000000000002 112.027 179.618 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.339 0 N-CA-C 112.652 -0.179 . . . . 2.0600000000000001 112.652 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.582 ' HA ' ' O ' ' A' ' 9' ' ' HIS . 7.2 t 57.8 43.12 0.3 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.355 0 CA-C-O 121.778 0.799 . . . . 4.7699999999999996 109.982 -177.004 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 81.1 14.15 79.72 Favored Glycine 0 N--CA 1.449 -0.449 0 CA-C-N 115.6 -0.727 . . . . 3.8199999999999998 112.626 -179.934 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 47.1 t-80 . . . . . 0 C--O 1.247 0.961 0 CA-C-O 118.736 -0.649 . . . . 6.0599999999999996 110.106 178.38 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 80.9 m-85 . . . . . 0 C--O 1.231 0.082 0 CA-C-O 120.648 0.261 . . . . 3.8100000000000001 110.602 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 65.2 mtm180 . . . . . 0 C--N 1.319 -0.748 0 CA-C-N 116.306 -0.407 . . . . 5.29 111.672 179.304 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 50.6 m . . . . . 0 N--CA 1.457 -0.12 0 N-CA-C 110.515 -0.18 . . . . 2.23 110.515 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . 50.42 63.28 10.24 Favored Pre-proline 0 N--CA 1.463 0.216 0 O-C-N 123.796 0.685 . . . . 1.49 109.841 -173.855 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.443 ' HB2' ' HA ' ' A' ' 15' ' ' HIS . 11.0 Cg_exo -68.68 107.24 1.61 Allowed 'Trans proline' 0 N--CA 1.46 -0.499 0 C-N-CA 122.753 2.302 . . . . 2.4199999999999999 113.291 -168.718 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -101.47 -142.42 12.69 Favored Glycine 0 N--CA 1.445 -0.709 0 CA-C-N 115.685 -0.689 . . . . 1.77 112.135 175.833 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' HIS . . . . . 0.422 ' O ' ' HA ' ' A' ' 13' ' ' VAL . 33.3 m80 -66.79 -40.05 88.0 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 111.883 0.327 . . . . 5.0899999999999999 111.883 -176.145 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 51.9 m . . . . . 0 CA--C 1.54 0.564 0 N-CA-C 112.03 0.382 . . . . 4.0300000000000002 112.03 -178.645 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.362 0 CA-C-O 120.152 -0.249 . . . . 2.0600000000000001 112.972 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.422 ' HA ' ' O ' ' A' ' 9' ' ' HIS . 7.7 t 55.34 42.02 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.462 0.162 0 CA-C-O 122.121 0.963 . . . . 4.7699999999999996 108.903 -175.682 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.461 ' O ' ' HB2' ' A' ' 15' ' ' HIS . . . 128.49 -52.31 0.83 Allowed Glycine 0 N--CA 1.442 -0.91 0 CA-C-N 114.861 -1.063 . . . . 3.8199999999999998 110.869 -174.387 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' HIS . . . . . 0.461 ' HB2' ' O ' ' A' ' 14' ' ' GLY . 38.7 t-80 . . . . . 0 C--O 1.245 0.84 0 C-N-CA 123.513 0.725 . . . . 6.0599999999999996 109.478 178.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' PHE . . . . . 0.458 ' HB3' ' HB ' ' A' ' 5' ' ' THR . 94.3 m-85 . . . . . 0 N--CA 1.464 0.235 0 CA-C-O 120.973 0.416 . . . . 3.8100000000000001 110.9 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 41.0 mtp180 . . . . . 0 C--N 1.325 -0.457 0 CA-C-N 115.762 -0.653 . . . . 5.29 112.428 -176.763 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' THR . . . . . 0.458 ' HB ' ' HB3' ' A' ' 2' ' ' PHE . 8.4 m . . . . . 0 N--CA 1.454 -0.236 0 N-CA-C 110.346 -0.242 . . . . 2.23 110.346 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . 51.0 64.09 8.75 Favored Pre-proline 0 C--O 1.234 0.26 0 N-CA-C 109.554 -0.536 . . . . 1.49 109.554 -173.627 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -57.64 97.62 0.08 OUTLIER 'Trans proline' 0 C--N 1.345 0.375 0 C-N-CA 123.597 2.865 . . . . 2.4199999999999999 113.738 -167.525 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -95.72 -150.09 26.55 Favored Glycine 0 N--CA 1.445 -0.704 0 CA-C-N 115.566 -0.743 . . . . 1.77 111.765 174.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 86.1 t60 -73.25 -43.31 61.35 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 120.598 0.237 . . . . 5.0899999999999999 111.452 -176.083 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 48.4 m . . . . . 0 C--N 1.323 -0.565 0 N-CA-C 111.949 0.352 . . . . 4.0300000000000002 111.949 -179.297 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.823 0 N-CA-C 112.369 -0.292 . . . . 2.0600000000000001 112.369 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 40.3 t -59.63 -32.6 49.57 Favored 'Isoleucine or valine' 0 C--O 1.234 0.258 0 CA-C-O 121.329 0.585 . . . . 4.7699999999999996 110.07 178.029 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -112.58 23.88 14.53 Favored Glycine 0 N--CA 1.447 -0.577 0 N-CA-C 111.062 -0.815 . . . . 3.8199999999999998 111.062 173.467 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 6.8 t60 . . . . . 0 C--O 1.248 0.99 0 CA-C-O 118.287 -0.864 . . . . 6.0599999999999996 110.16 -178.505 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 29.6 p90 . . . . . 0 N--CA 1.458 -0.039 0 CA-C-O 121.387 0.613 . . . . 3.8100000000000001 110.661 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 18.2 mtp180 . . . . . 0 C--N 1.322 -0.617 0 CA-C-N 115.934 -0.575 . . . . 5.29 112.32 -178.969 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 40.9 p . . . . . 0 N--CA 1.454 -0.229 0 CA-C-O 120.905 0.383 . . . . 2.23 110.177 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . 57.72 68.81 1.78 Allowed Pre-proline 0 N--CA 1.462 0.128 0 CA-C-N 115.475 -0.784 . . . . 1.49 109.806 -172.533 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_exo -56.25 99.73 0.08 OUTLIER 'Trans proline' 0 C--N 1.347 0.486 0 C-N-CA 123.616 2.877 . . . . 2.4199999999999999 113.756 -169.92 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -104.07 -130.77 6.97 Favored Glycine 0 N--CA 1.442 -0.906 0 CA-C-N 115.634 -0.712 . . . . 1.77 111.73 174.658 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 39.7 m80 -86.26 -59.14 2.37 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.882 0.372 . . . . 5.0899999999999999 110.719 -176.465 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 55.9 m . . . . . 0 CA--C 1.539 0.535 0 N-CA-C 112.572 0.582 . . . . 4.0300000000000002 112.572 -178.588 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.444 ' HA3' ' O ' ' A' ' 15' ' ' HIS . . . . . . . . 0 C--O 1.23 -0.123 0 CA-C-O 120.007 -0.329 . . . . 2.0600000000000001 113.667 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 6.3 t 53.24 42.62 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.331 0 CA-C-O 121.83 0.824 . . . . 4.7699999999999996 109.622 -175.778 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 112.12 -29.66 8.24 Favored Glycine 0 N--CA 1.447 -0.602 0 CA-C-N 115.59 -0.732 . . . . 3.8199999999999998 112.456 -177.213 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' HIS . . . . . 0.444 ' O ' ' HA3' ' A' ' 12' ' ' GLY . 83.3 t60 . . . . . 0 C--O 1.246 0.891 0 CA-C-O 118.905 -0.569 . . . . 6.0599999999999996 109.95 -178.58 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 92.1 m-85 . . . . . 0 C--O 1.232 0.176 0 CA-C-O 121.198 0.523 . . . . 3.8100000000000001 110.103 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 65.1 mtp180 . . . . . 0 C--N 1.322 -0.598 0 N-CA-C 112.933 0.716 . . . . 5.29 112.933 -175.875 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 22.7 p . . . . . 0 C--O 1.234 0.257 0 N-CA-C 110.79 -0.078 . . . . 2.23 110.79 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . 55.98 74.57 0.68 Allowed Pre-proline 0 C--O 1.232 0.172 0 O-C-N 123.811 0.694 . . . . 1.49 110.646 -177.013 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_exo -51.56 94.38 0.03 OUTLIER 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 124.12 3.214 . . . . 2.4199999999999999 114.144 -174.836 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -89.76 -164.97 40.46 Favored Glycine 0 N--CA 1.445 -0.714 0 N-CA-C 111.432 -0.667 . . . . 1.77 111.432 172.456 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' HIS . . . . . 0.591 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 55.5 t-80 -67.82 -25.43 65.56 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.798 0.333 . . . . 5.0899999999999999 111.049 -178.255 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 45.3 t . . . . . 0 CA--C 1.54 0.571 0 CA-C-O 119.374 -0.346 . . . . 4.0300000000000002 111.383 177.429 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.445 -0.762 0 N-CA-C 112.36 -0.296 . . . . 2.0600000000000001 112.36 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.591 ' HB ' ' O ' ' A' ' 9' ' ' HIS . 7.3 p -60.57 -36.74 72.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-O 120.865 0.364 . . . . 4.7699999999999996 110.858 177.575 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -115.09 -23.06 4.7 Favored Glycine 0 N--CA 1.446 -0.666 0 C-N-CA 120.771 -0.728 . . . . 3.8199999999999998 112.308 179.652 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 54.8 t-80 . . . . . 0 C--O 1.248 1.007 0 CA-C-O 118.48 -0.771 . . . . 6.0599999999999996 110.107 -179.664 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 66.3 m-85 . . . . . 0 N--CA 1.454 -0.249 0 N-CA-C 109.821 -0.437 . . . . 3.8100000000000001 109.821 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 . . . . . 0 C--N 1.322 -0.592 0 CA-C-O 118.986 -0.531 . . . . 5.29 112.171 -176.296 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 96.8 m . . . . . 0 N--CA 1.454 -0.253 0 N-CA-C 108.814 -0.81 . . . . 2.23 108.814 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . 57.25 73.69 0.75 Allowed Pre-proline 0 C--O 1.233 0.232 0 CA-C-O 121.252 0.549 . . . . 1.49 109.69 -174.093 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 25.0 Cg_exo -63.2 137.49 61.51 Favored 'Trans proline' 0 C--O 1.235 0.329 0 C-N-CA 123.426 2.75 . . . . 2.4199999999999999 113.395 -170.734 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -147.02 -70.69 0.01 OUTLIER Glycine 0 N--CA 1.446 -0.687 0 C-N-CA 120.889 -0.672 . . . . 1.77 112.739 177.807 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 85.4 t60 -87.53 -81.59 0.24 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.862 0.331 . . . . 5.0899999999999999 111.723 -174.737 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 5.3 p . . . . . 0 CA--C 1.54 0.575 0 N-CA-C 113.233 0.827 . . . . 4.0300000000000002 113.233 -174.964 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.441 -0.973 0 N-CA-C 110.764 -0.934 . . . . 2.0600000000000001 110.764 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 7.7 p -88.34 -30.28 5.45 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 N-CA-C 109.419 -0.585 . . . . 4.7699999999999996 109.419 173.822 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -148.46 14.61 1.24 Allowed Glycine 0 N--CA 1.448 -0.536 0 CA-C-N 115.606 -0.725 . . . . 3.8199999999999998 111.78 176.792 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 58.5 t-80 . . . . . 0 C--O 1.249 1.028 0 CA-C-O 118.453 -0.784 . . . . 6.0599999999999996 110.445 -178.15 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 99.0 m-85 . . . . . 0 N--CA 1.463 0.176 0 CA-C-O 121.214 0.53 . . . . 3.8100000000000001 110.393 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 73.7 mtm180 . . . . . 0 C--N 1.322 -0.591 0 N-CA-C 113.393 0.886 . . . . 5.29 113.393 -176.023 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 9.2 m . . . . . 0 N--CA 1.452 -0.347 0 CA-C-O 120.471 0.177 . . . . 2.23 111.065 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . 57.75 73.62 0.74 Allowed Pre-proline 0 N--CA 1.466 0.35 0 CA-C-N 115.991 -0.55 . . . . 1.49 112.106 179.042 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.573 ' HB3' ' H ' ' A' ' 13' ' ' VAL . 6.0 Cg_endo -49.04 143.92 17.03 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 123.622 2.882 . . . . 2.4199999999999999 113.558 179.472 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 179.22 -112.88 0.38 Allowed Glycine 0 N--CA 1.446 -0.691 0 C-N-CA 120.74 -0.743 . . . . 1.77 112.671 176.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 16.4 t60 -82.01 -70.87 0.51 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.571 0.185 . . . . 5.0899999999999999 110.881 -177.581 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 19.1 t . . . . . 0 CA--C 1.537 0.461 0 C-N-CA 120.756 -0.378 . . . . 4.0300000000000002 110.247 176.9 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.698 0 N-CA-C 112.802 -0.119 . . . . 2.0600000000000001 112.802 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.573 ' H ' ' HB3' ' A' ' 7' ' ' PRO . 52.3 t -67.75 -41.23 85.06 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-O 121.068 0.461 . . . . 4.7699999999999996 110.11 177.222 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -126.89 18.6 6.23 Favored Glycine 0 N--CA 1.448 -0.517 0 C-N-CA 121.04 -0.6 . . . . 3.8199999999999998 111.622 175.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 9.4 t60 . . . . . 0 C--O 1.243 0.753 0 CA-C-O 118.44 -0.79 . . . . 6.0599999999999996 109.891 -176.775 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 84.4 m-85 . . . . . 0 N--CA 1.464 0.273 0 CA-C-O 121.184 0.516 . . . . 3.8100000000000001 110.831 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' ARG . . . . . 0.623 ' O ' ' HG3' ' A' ' 7' ' ' PRO . 99.5 mtt180 . . . . . 0 CA--C 1.539 0.546 0 CA-C-N 115.726 -0.67 . . . . 5.29 112.552 -176.8 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 3.9 t . . . . . 0 N--CA 1.453 -0.278 0 CA-C-O 121.42 0.629 . . . . 2.23 111.803 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . 52.29 73.59 0.93 Allowed Pre-proline 0 C--N 1.33 -0.256 0 CA-C-N 115.07 -0.968 . . . . 1.49 112.507 177.752 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.623 ' HG3' ' O ' ' A' ' 3' ' ' ARG . 5.9 Cg_endo -84.6 -53.65 0.03 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.616 0 C-N-CA 123.17 2.58 . . . . 2.4199999999999999 111.069 177.367 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -143.96 68.58 0.42 Allowed Glycine 0 N--CA 1.443 -0.858 0 N-CA-C 109.985 -1.246 . . . . 1.77 109.985 174.916 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 99.5 m-70 71.67 -61.7 0.48 Allowed 'General case' 0 N--CA 1.468 0.454 0 C-N-CA 123.571 0.748 . . . . 5.0899999999999999 110.805 -173.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 26.1 m . . . . . 0 C--N 1.325 -0.492 0 CA-C-N 116.677 -0.238 . . . . 4.0300000000000002 110.8 179.636 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.471 0 N-CA-C 112.159 -0.376 . . . . 2.0600000000000001 112.159 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 6.3 m -67.95 83.1 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-O 121.666 0.746 . . . . 4.7699999999999996 110.049 172.747 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 130.99 -15.93 5.33 Favored Glycine 0 N--CA 1.445 -0.76 0 CA-C-N 115.39 -0.823 . . . . 3.8199999999999998 111.354 -174.003 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 73.3 t60 . . . . . 0 C--O 1.245 0.817 0 CA-C-O 118.758 -0.639 . . . . 6.0599999999999996 109.579 178.091 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 76.5 m-85 . . . . . 0 N--CA 1.454 -0.268 0 CA-C-O 120.942 0.401 . . . . 3.8100000000000001 110.512 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 84.1 mtt180 . . . . . 0 C--N 1.321 -0.665 0 CA-C-O 119.086 -0.483 . . . . 5.29 111.684 176.631 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 10.9 p . . . . . 0 C--O 1.235 0.293 0 N-CA-C 109.741 -0.466 . . . . 2.23 109.741 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . 66.23 94.91 0.05 OUTLIER Pre-proline 0 C--N 1.333 -0.137 0 CA-C-N 115.52 -0.764 . . . . 1.49 110.754 -177.725 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_exo -64.88 102.92 0.44 Allowed 'Trans proline' 0 C--O 1.232 0.222 0 C-N-CA 122.702 2.268 . . . . 2.4199999999999999 112.31 -179.417 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -160.98 51.52 0.34 Allowed Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 120.901 -0.666 . . . . 1.77 112.223 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 40.4 t-80 -174.23 -47.35 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.23 0.538 . . . . 5.0899999999999999 109.73 -179.421 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 23.3 t . . . . . 0 C--N 1.323 -0.564 0 CA-C-N 115.345 -0.843 . . . . 4.0300000000000002 110.259 -177.147 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.808 0 N-CA-C 112.255 -0.338 . . . . 2.0600000000000001 112.255 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 73.4 t -62.2 -52.95 54.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 N-CA-C 109.414 -0.587 . . . . 4.7699999999999996 109.414 178.478 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -107.04 23.41 27.51 Favored Glycine 0 N--CA 1.443 -0.863 0 N-CA-C 110.782 -0.927 . . . . 3.8199999999999998 110.782 172.773 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 41.9 m80 . . . . . 0 C--O 1.25 1.089 0 CA-C-N 115.089 -0.556 . . . . 6.0599999999999996 110.403 -176.476 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 75.5 m-85 . . . . . 0 N--CA 1.453 -0.283 0 CA-C-O 121.19 0.519 . . . . 3.8100000000000001 109.726 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 47.6 mtm-85 . . . . . 0 C--N 1.325 -0.488 0 CA-C-N 115.842 -0.617 . . . . 5.29 111.964 -176.162 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 8.9 t . . . . . 0 N--CA 1.449 -0.51 0 N-CA-C 108.442 -0.947 . . . . 2.23 108.442 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . 50.65 63.19 10.31 Favored Pre-proline 0 CA--C 1.531 0.232 0 N-CA-C 109.757 -0.46 . . . . 1.49 109.757 -170.679 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -59.65 140.68 94.79 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 123.237 2.625 . . . . 2.4199999999999999 113.26 -170.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -144.91 -53.41 0.03 OUTLIER Glycine 0 N--CA 1.448 -0.558 0 C-N-CA 120.766 -0.73 . . . . 1.77 112.473 178.866 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 60.1 m80 -97.02 -105.56 0.17 Allowed 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.653 0.263 . . . . 5.0899999999999999 111.349 -178.495 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 47.0 t . . . . . 0 CA--C 1.538 0.486 0 CA-C-O 119.269 -0.396 . . . . 4.0300000000000002 111.821 -179.509 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.827 0 N-CA-C 112.433 -0.267 . . . . 2.0600000000000001 112.433 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 8.0 p -99.47 -28.43 3.44 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-O 121.387 0.613 . . . . 4.7699999999999996 109.539 174.829 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -135.66 0.72 3.46 Favored Glycine 0 N--CA 1.448 -0.508 0 CA-C-N 115.498 -0.774 . . . . 3.8199999999999998 111.789 176.888 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 82.9 t60 . . . . . 0 C--O 1.245 0.832 0 CA-C-O 118.439 -0.791 . . . . 6.0599999999999996 109.874 179.712 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 0.983 0 CA-C-O 120.696 0.284 . . . . 4.5599999999999996 110.357 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . 0.487 ' HB3' ' OG1' ' A' ' 5' ' ' THR . 98.8 m-85 -99.38 88.98 4.03 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 121.223 0.535 . . . . 3.8100000000000001 109.928 179.259 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . 0.432 ' HB2' ' HD ' ' A' ' 4' ' ' HZP . 51.4 mtm180 -68.32 -52.22 35.93 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.417 -0.81 . . . . 5.29 112.574 -175.434 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' HZP . . . . . 0.432 ' HD ' ' HB2' ' A' ' 3' ' ' ARG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.487 ' OG1' ' HB3' ' A' ' 2' ' ' PHE . 14.6 m -98.62 90.87 4.88 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 109.777 -0.453 . . . . 2.23 109.777 -175.667 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . 56.36 69.26 1.86 Allowed Pre-proline 0 C--N 1.331 -0.21 0 CA-C-N 115.391 -0.822 . . . . 1.49 109.608 -171.592 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.452 ' HA ' ' HB ' ' A' ' 11' ' ' HZP . 14.6 Cg_endo -55.99 93.85 0.05 OUTLIER 'Trans proline' 0 C--N 1.348 0.53 0 C-N-CA 123.325 2.683 . . . . 2.4199999999999999 113.339 -173.261 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -98.59 -139.97 11.15 Favored Glycine 0 N--CA 1.446 -0.651 0 C-N-CA 120.769 -0.729 . . . . 1.77 112.74 179.081 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . 0.582 ' O ' ' HA ' ' A' ' 13' ' ' VAL . 74.9 t60 -70.25 -43.35 70.71 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 111.594 0.22 . . . . 5.0899999999999999 111.594 -173.695 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.474 ' HB2' ' HD ' ' A' ' 11' ' ' HZP . 18.0 m -93.62 -49.63 5.78 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 112.027 0.381 . . . . 4.0300000000000002 112.027 179.618 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' HZP . . . . . 0.474 ' HD ' ' HB2' ' A' ' 10' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -96.74 -5.56 58.64 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.587 -0.816 . . . . 2.0600000000000001 112.652 -176.852 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.582 ' HA ' ' O ' ' A' ' 9' ' ' HIS . 7.2 t 57.8 43.12 0.3 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.355 0 CA-C-O 121.778 0.799 . . . . 4.7699999999999996 109.982 -177.004 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 81.1 14.15 79.72 Favored Glycine 0 N--CA 1.449 -0.449 0 CA-C-N 115.6 -0.727 . . . . 3.8199999999999998 112.626 -179.934 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 47.1 t-80 . . . . . 0 C--O 1.247 0.961 0 CA-C-O 118.736 -0.649 . . . . 6.0599999999999996 110.106 178.38 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.069 0 CA-C-O 120.609 0.243 . . . . 4.5599999999999996 110.928 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 80.9 m-85 -83.76 160.92 21.15 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.648 0.261 . . . . 3.8100000000000001 110.602 -179.352 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . 0.475 ' HB2' ' HD ' ' A' ' 4' ' ' HZP . 65.2 mtm180 -72.87 -53.1 12.28 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 116.306 -0.407 . . . . 5.29 111.672 179.304 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' HZP . . . . . 0.475 ' HD ' ' HB2' ' A' ' 3' ' ' ARG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 50.6 m -127.06 107.82 10.38 Favored 'General case' 0 C--N 1.326 -0.442 0 C-N-CA 120.967 -0.293 . . . . 2.23 110.515 -177.906 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . 50.42 63.28 10.24 Favored Pre-proline 0 N--CA 1.463 0.216 0 O-C-N 123.796 0.685 . . . . 1.49 109.841 -173.855 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.533 ' HA ' ' HB ' ' A' ' 11' ' ' HZP . 11.0 Cg_exo -68.68 107.24 1.61 Allowed 'Trans proline' 0 N--CA 1.46 -0.499 0 C-N-CA 122.753 2.302 . . . . 2.4199999999999999 113.291 -168.718 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -101.47 -142.42 12.69 Favored Glycine 0 N--CA 1.445 -0.709 0 CA-C-N 115.685 -0.689 . . . . 1.77 112.135 175.833 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . 0.422 ' O ' ' HA ' ' A' ' 13' ' ' VAL . 33.3 m80 -66.79 -40.05 88.0 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 111.883 0.327 . . . . 5.0899999999999999 111.883 -176.145 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.546 ' HB2' ' HD ' ' A' ' 11' ' ' HZP . 51.9 m -85.72 -55.44 3.98 Favored 'General case' 0 CA--C 1.54 0.564 0 N-CA-C 112.03 0.382 . . . . 4.0300000000000002 112.03 -178.645 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' HZP . . . . . 0.546 ' HD ' ' HB2' ' A' ' 10' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -91.91 6.16 79.25 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.784 -0.722 . . . . 2.0600000000000001 112.972 -177.144 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.422 ' HA ' ' O ' ' A' ' 9' ' ' HIS . 7.7 t 55.34 42.02 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.462 0.162 0 CA-C-O 122.121 0.963 . . . . 4.7699999999999996 108.903 -175.682 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.461 ' O ' ' HB2' ' A' ' 15' ' ' HIS . . . 128.49 -52.31 0.83 Allowed Glycine 0 N--CA 1.442 -0.91 0 CA-C-N 114.861 -1.063 . . . . 3.8199999999999998 110.869 -174.387 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' HIS . . . . . 0.461 ' HB2' ' O ' ' A' ' 14' ' ' GLY . 38.7 t-80 . . . . . 0 C--O 1.245 0.84 0 C-N-CA 123.513 0.725 . . . . 6.0599999999999996 109.478 178.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.012 0 N-CA-C 110.221 -0.288 . . . . 4.5599999999999996 110.221 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . 0.458 ' HB3' ' HB ' ' A' ' 5' ' ' THR . 94.3 m-85 60.11 65.17 1.13 Allowed 'General case' 0 N--CA 1.464 0.235 0 O-C-N 123.476 0.485 . . . . 3.8100000000000001 110.9 179.566 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 41.0 mtp180 -70.4 -50.35 39.49 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.762 -0.653 . . . . 5.29 112.428 -176.763 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' HZP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.458 ' HB ' ' HB3' ' A' ' 2' ' ' PHE . 8.4 m -94.85 102.02 13.85 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.617 -0.265 . . . . 2.23 110.346 -173.903 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . 51.0 64.09 8.75 Favored Pre-proline 0 C--O 1.234 0.26 0 N-CA-C 109.554 -0.536 . . . . 1.49 109.554 -173.627 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -57.64 97.62 0.08 OUTLIER 'Trans proline' 0 C--N 1.345 0.375 0 C-N-CA 123.597 2.865 . . . . 2.4199999999999999 113.738 -167.525 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -95.72 -150.09 26.55 Favored Glycine 0 N--CA 1.445 -0.704 0 CA-C-N 115.566 -0.743 . . . . 1.77 111.765 174.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 86.1 t60 -73.25 -43.31 61.35 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 120.598 0.237 . . . . 5.0899999999999999 111.452 -176.083 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.493 ' HB2' ' HD ' ' A' ' 11' ' ' HZP . 48.4 m -78.94 -48.3 14.79 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 111.949 0.352 . . . . 4.0300000000000002 111.949 -179.297 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' HZP . . . . . 0.493 ' HD ' ' HB2' ' A' ' 10' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 140.93 103.39 0.52 Allowed Glycine 0 N--CA 1.444 -0.823 0 C-N-CA 120.951 -0.642 . . . . 2.0600000000000001 112.369 175.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 40.3 t -59.63 -32.6 49.57 Favored 'Isoleucine or valine' 0 C--O 1.234 0.258 0 CA-C-O 121.329 0.585 . . . . 4.7699999999999996 110.07 178.029 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -112.58 23.88 14.53 Favored Glycine 0 N--CA 1.447 -0.577 0 N-CA-C 111.062 -0.815 . . . . 3.8199999999999998 111.062 173.467 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 6.8 t60 . . . . . 0 C--O 1.248 0.99 0 CA-C-O 118.287 -0.864 . . . . 6.0599999999999996 110.16 -178.505 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.949 0 CA-C-O 120.551 0.215 . . . . 4.5599999999999996 110.752 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . 0.568 ' O ' ' HBA' ' A' ' 11' ' ' HZP . 29.6 p90 -137.07 38.41 2.55 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.387 0.613 . . . . 3.8100000000000001 110.661 -179.059 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . 0.517 ' HG2' ' O ' ' A' ' 11' ' ' HZP . 18.2 mtp180 -64.62 -50.5 66.91 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.934 -0.575 . . . . 5.29 112.32 -178.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' HZP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 40.9 p -90.36 82.52 5.94 Favored 'General case' 0 C--N 1.326 -0.429 0 C-N-CA 120.437 -0.505 . . . . 2.23 110.177 -179.778 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . 57.72 68.81 1.78 Allowed Pre-proline 0 N--CA 1.462 0.128 0 CA-C-N 115.475 -0.784 . . . . 1.49 109.806 -172.533 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_exo -56.25 99.73 0.08 OUTLIER 'Trans proline' 0 C--N 1.347 0.486 0 C-N-CA 123.616 2.877 . . . . 2.4199999999999999 113.756 -169.92 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -104.07 -130.77 6.97 Favored Glycine 0 N--CA 1.442 -0.906 0 CA-C-N 115.634 -0.712 . . . . 1.77 111.73 174.658 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 39.7 m80 -86.26 -59.14 2.37 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.882 0.372 . . . . 5.0899999999999999 110.719 -176.465 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.467 ' HB2' ' HD ' ' A' ' 11' ' ' HZP . 55.9 m -62.4 -48.75 78.34 Favored 'General case' 0 CA--C 1.539 0.535 0 N-CA-C 112.572 0.582 . . . . 4.0300000000000002 112.572 -178.588 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' HZP . . . . . 0.568 ' HBA' ' O ' ' A' ' 2' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.444 ' HA3' ' O ' ' A' ' 15' ' ' HIS . . . -132.9 15.99 4.79 Favored Glycine 0 C--N 1.329 0.149 0 C-N-CA 119.705 -1.235 . . . . 2.0600000000000001 113.667 -176.201 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 6.3 t 53.24 42.62 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.331 0 CA-C-O 121.83 0.824 . . . . 4.7699999999999996 109.622 -175.778 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 112.12 -29.66 8.24 Favored Glycine 0 N--CA 1.447 -0.602 0 CA-C-N 115.59 -0.732 . . . . 3.8199999999999998 112.456 -177.213 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' HIS . . . . . 0.444 ' O ' ' HA3' ' A' ' 12' ' ' GLY . 83.3 t60 . . . . . 0 C--O 1.246 0.891 0 CA-C-O 118.905 -0.569 . . . . 6.0599999999999996 109.95 -178.58 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.936 0 N-CA-C 110.28 -0.267 . . . . 4.5599999999999996 110.28 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 92.1 m-85 -72.33 122.19 20.73 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 121.198 0.523 . . . . 3.8100000000000001 110.103 178.166 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . 0.449 ' HB3' ' O ' ' A' ' 11' ' ' HZP . 65.1 mtp180 -80.04 -47.82 14.28 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 112.933 0.716 . . . . 5.29 112.933 -175.875 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' HZP . . . . . 0.438 ' HDA' ' N ' ' A' ' 3' ' ' ARG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 22.7 p -114.26 110.94 20.72 Favored 'General case' 0 C--N 1.323 -0.552 0 O-C-N 122.364 -0.21 . . . . 2.23 110.79 -177.778 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . 55.98 74.57 0.68 Allowed Pre-proline 0 C--O 1.232 0.172 0 O-C-N 123.811 0.694 . . . . 1.49 110.646 -177.013 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_exo -51.56 94.38 0.03 OUTLIER 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 124.12 3.214 . . . . 2.4199999999999999 114.144 -174.836 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -89.76 -164.97 40.46 Favored Glycine 0 N--CA 1.445 -0.714 0 N-CA-C 111.432 -0.667 . . . . 1.77 111.432 172.456 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . 0.591 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 55.5 t-80 -67.82 -25.43 65.56 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.798 0.333 . . . . 5.0899999999999999 111.049 -178.255 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.531 ' HB3' ' HD ' ' A' ' 11' ' ' HZP . 45.3 t -101.9 -53.14 3.01 Favored 'General case' 0 CA--C 1.54 0.571 0 CA-C-O 119.374 -0.346 . . . . 4.0300000000000002 111.383 177.429 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' HZP . . . . . 0.531 ' HD ' ' HB3' ' A' ' 10' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -140.68 58.99 0.57 Allowed Glycine 0 N--CA 1.445 -0.762 0 C-N-CA 120.491 -0.861 . . . . 2.0600000000000001 112.36 -175.257 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.591 ' HB ' ' O ' ' A' ' 9' ' ' HIS . 7.3 p -60.57 -36.74 72.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-O 120.865 0.364 . . . . 4.7699999999999996 110.858 177.575 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -115.09 -23.06 4.7 Favored Glycine 0 N--CA 1.446 -0.666 0 C-N-CA 120.771 -0.728 . . . . 3.8199999999999998 112.308 179.652 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 54.8 t-80 . . . . . 0 C--O 1.248 1.007 0 CA-C-O 118.48 -0.771 . . . . 6.0599999999999996 110.107 -179.664 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.039 0 CA-C-O 120.605 0.241 . . . . 4.5599999999999996 110.648 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 66.3 m-85 -89.86 174.64 7.58 Favored 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 109.821 -0.437 . . . . 3.8100000000000001 109.821 174.415 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . 0.613 ' O ' ' HG ' ' A' ' 11' ' ' HZP . 99.8 mtt180 -68.11 -63.39 1.07 Allowed 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 118.986 -0.531 . . . . 5.29 112.171 -176.296 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' HZP . . . . . 0.452 ' C ' ' HG1' ' A' ' 5' ' ' THR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.452 ' HG1' ' C ' ' A' ' 4' ' ' HZP . 96.8 m -162.12 125.28 3.01 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 108.814 -0.81 . . . . 2.23 108.814 -177.755 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . 57.25 73.69 0.75 Allowed Pre-proline 0 C--O 1.233 0.232 0 CA-C-O 121.252 0.549 . . . . 1.49 109.69 -174.093 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 25.0 Cg_exo -63.2 137.49 61.51 Favored 'Trans proline' 0 C--O 1.235 0.329 0 C-N-CA 123.426 2.75 . . . . 2.4199999999999999 113.395 -170.734 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -147.02 -70.69 0.01 OUTLIER Glycine 0 N--CA 1.446 -0.687 0 C-N-CA 120.889 -0.672 . . . . 1.77 112.739 177.807 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 85.4 t60 -87.53 -81.59 0.24 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.862 0.331 . . . . 5.0899999999999999 111.723 -174.737 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.594 ' N ' ' HDA' ' A' ' 11' ' ' HZP . 5.3 p -90.3 -42.32 11.04 Favored 'General case' 0 CA--C 1.54 0.575 0 N-CA-C 113.233 0.827 . . . . 4.0300000000000002 113.233 -174.964 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' HZP . . . . . 0.613 ' HG ' ' O ' ' A' ' 3' ' ' ARG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 160.38 -177.13 36.94 Favored Glycine 0 N--CA 1.441 -0.973 0 CA-C-N 114.528 -1.215 . . . . 2.0600000000000001 110.764 176.356 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 7.7 p -88.34 -30.28 5.45 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 N-CA-C 109.419 -0.585 . . . . 4.7699999999999996 109.419 173.822 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -148.46 14.61 1.24 Allowed Glycine 0 N--CA 1.448 -0.536 0 CA-C-N 115.606 -0.725 . . . . 3.8199999999999998 111.78 176.792 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 58.5 t-80 . . . . . 0 C--O 1.249 1.028 0 CA-C-O 118.453 -0.784 . . . . 6.0599999999999996 110.445 -178.15 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.115 0 N-CA-C 110.451 -0.203 . . . . 4.5599999999999996 110.451 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 99.0 m-85 55.84 65.25 1.5 Allowed 'General case' 0 N--CA 1.463 0.176 0 CA-C-O 121.214 0.53 . . . . 3.8100000000000001 110.393 -179.441 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . 0.513 ' HA ' ' HA ' ' A' ' 11' ' ' HZP . 73.7 mtm180 -64.62 -44.09 91.68 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 113.393 0.886 . . . . 5.29 113.393 -176.023 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' HZP . . . . . 0.512 ' HDA' ' N ' ' A' ' 3' ' ' ARG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 9.2 m -126.64 112.88 15.99 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 120.471 0.177 . . . . 2.23 111.065 -177.537 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . 57.75 73.62 0.74 Allowed Pre-proline 0 N--CA 1.466 0.35 0 CA-C-N 115.991 -0.55 . . . . 1.49 112.106 179.042 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.573 ' HB3' ' H ' ' A' ' 13' ' ' VAL . 6.0 Cg_endo -49.04 143.92 17.03 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 123.622 2.882 . . . . 2.4199999999999999 113.558 179.472 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 179.22 -112.88 0.38 Allowed Glycine 0 N--CA 1.446 -0.691 0 C-N-CA 120.74 -0.743 . . . . 1.77 112.671 176.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 16.4 t60 -82.01 -70.87 0.51 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.571 0.185 . . . . 5.0899999999999999 110.881 -177.581 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.599 ' HB3' ' HD ' ' A' ' 11' ' ' HZP . 19.1 t -71.51 -52.42 18.41 Favored 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 120.756 -0.378 . . . . 4.0300000000000002 110.247 176.9 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' HZP . . . . . 0.599 ' HD ' ' HB3' ' A' ' 10' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -164.2 68.07 0.21 Allowed Glycine 0 N--CA 1.446 -0.698 0 C-N-CA 119.724 -1.227 . . . . 2.0600000000000001 112.802 -175.595 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.573 ' H ' ' HB3' ' A' ' 7' ' ' PRO . 52.3 t -67.75 -41.23 85.06 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-O 121.068 0.461 . . . . 4.7699999999999996 110.11 177.222 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -126.89 18.6 6.23 Favored Glycine 0 N--CA 1.448 -0.517 0 C-N-CA 121.04 -0.6 . . . . 3.8199999999999998 111.622 175.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 9.4 t60 . . . . . 0 C--O 1.243 0.753 0 CA-C-O 118.44 -0.79 . . . . 6.0599999999999996 109.891 -176.775 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.009 0 CA-C-O 120.264 0.078 . . . . 4.5599999999999996 110.965 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 84.4 m-85 58.38 49.17 11.24 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-O 121.184 0.516 . . . . 3.8100000000000001 110.831 -178.425 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . 0.623 ' O ' ' HG3' ' A' ' 7' ' ' PRO . 99.5 mtt180 -75.91 -45.54 34.73 Favored 'General case' 0 CA--C 1.539 0.546 0 CA-C-N 115.726 -0.67 . . . . 5.29 112.552 -176.8 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' HZP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 3.9 t -140.89 77.66 1.61 Allowed 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.42 0.629 . . . . 2.23 111.803 -174.579 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . 52.29 73.59 0.93 Allowed Pre-proline 0 C--N 1.33 -0.256 0 CA-C-N 115.07 -0.968 . . . . 1.49 112.507 177.752 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.623 ' HG3' ' O ' ' A' ' 3' ' ' ARG . 5.9 Cg_endo -84.6 -53.65 0.03 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.616 0 C-N-CA 123.17 2.58 . . . . 2.4199999999999999 111.069 177.367 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -143.96 68.58 0.42 Allowed Glycine 0 N--CA 1.443 -0.858 0 N-CA-C 109.985 -1.246 . . . . 1.77 109.985 174.916 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 99.5 m-70 71.67 -61.7 0.48 Allowed 'General case' 0 N--CA 1.468 0.454 0 C-N-CA 123.571 0.748 . . . . 5.0899999999999999 110.805 -173.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 26.1 m -95.7 122.56 38.59 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.677 -0.238 . . . . 4.0300000000000002 110.8 179.636 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' HZP . . . . . 0.475 ' HA ' ' CD ' ' A' ' 7' ' ' PRO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -172.34 -19.33 0.02 OUTLIER Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 120.692 -0.766 . . . . 2.0600000000000001 112.159 -178.012 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 6.3 m -67.95 83.1 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-O 121.666 0.746 . . . . 4.7699999999999996 110.049 172.747 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 130.99 -15.93 5.33 Favored Glycine 0 N--CA 1.445 -0.76 0 CA-C-N 115.39 -0.823 . . . . 3.8199999999999998 111.354 -174.003 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 73.3 t60 . . . . . 0 C--O 1.245 0.817 0 CA-C-O 118.758 -0.639 . . . . 6.0599999999999996 109.579 178.091 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.97 0 CA-C-O 120.975 0.417 . . . . 4.5599999999999996 110.493 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 76.5 m-85 -112.74 112.46 23.97 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.147 -0.479 . . . . 3.8100000000000001 110.512 179.352 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . 0.51 ' O ' ' HBA' ' A' ' 11' ' ' HZP . 84.1 mtt180 -82.66 -50.91 8.24 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 119.086 -0.483 . . . . 5.29 111.684 176.631 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' HZP . . . . . 0.428 ' HDA' ' N ' ' A' ' 3' ' ' ARG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 10.9 p -143.85 84.83 1.8 Allowed 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 116.124 -0.489 . . . . 2.23 109.741 177.456 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . 66.23 94.91 0.05 OUTLIER Pre-proline 0 C--N 1.333 -0.137 0 CA-C-N 115.52 -0.764 . . . . 1.49 110.754 -177.725 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_exo -64.88 102.92 0.44 Allowed 'Trans proline' 0 C--O 1.232 0.222 0 C-N-CA 122.702 2.268 . . . . 2.4199999999999999 112.31 -179.417 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -160.98 51.52 0.34 Allowed Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 120.901 -0.666 . . . . 1.77 112.223 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 40.4 t-80 -174.23 -47.35 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.23 0.538 . . . . 5.0899999999999999 109.73 -179.421 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.643 ' N ' ' HDA' ' A' ' 11' ' ' HZP . 23.3 t -167.04 -47.83 0.02 OUTLIER 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.345 -0.843 . . . . 4.0300000000000002 110.259 -177.147 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' HZP . . . . . 0.643 ' HDA' ' N ' ' A' ' 10' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -146.83 46.09 0.75 Allowed Glycine 0 N--CA 1.444 -0.808 0 C-N-CA 120.542 -0.837 . . . . 2.0600000000000001 112.255 -177.573 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 73.4 t -62.2 -52.95 54.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 N-CA-C 109.414 -0.587 . . . . 4.7699999999999996 109.414 178.478 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -107.04 23.41 27.51 Favored Glycine 0 N--CA 1.443 -0.863 0 N-CA-C 110.782 -0.927 . . . . 3.8199999999999998 110.782 172.773 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 41.9 m80 . . . . . 0 C--O 1.25 1.089 0 CA-C-N 115.089 -0.556 . . . . 6.0599999999999996 110.403 -176.476 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.968 0 CA-C-O 121.011 0.434 . . . . 4.5599999999999996 110.758 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 75.5 m-85 -133.44 65.48 1.58 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.19 0.519 . . . . 3.8100000000000001 109.726 176.584 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . 0.479 ' HB2' ' HD ' ' A' ' 4' ' ' HZP . 47.6 mtm-85 -87.97 -57.51 2.91 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.842 -0.617 . . . . 5.29 111.964 -176.162 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' HZP . . . . . 0.479 ' HD ' ' HB2' ' A' ' 3' ' ' ARG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 8.9 t -158.86 132.52 7.48 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 108.442 -0.947 . . . . 2.23 108.442 177.602 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . 50.65 63.19 10.31 Favored Pre-proline 0 CA--C 1.531 0.232 0 N-CA-C 109.757 -0.46 . . . . 1.49 109.757 -170.679 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.401 ' HB3' ' HB ' ' A' ' 11' ' ' HZP . 31.3 Cg_exo -59.65 140.68 94.79 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 123.237 2.625 . . . . 2.4199999999999999 113.26 -170.953 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -144.91 -53.41 0.03 OUTLIER Glycine 0 N--CA 1.448 -0.558 0 C-N-CA 120.766 -0.73 . . . . 1.77 112.473 178.866 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 60.1 m80 -97.02 -105.56 0.17 Allowed 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.653 0.263 . . . . 5.0899999999999999 111.349 -178.495 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.598 ' N ' ' HDA' ' A' ' 11' ' ' HZP . 47.0 t -66.57 -45.53 78.99 Favored 'General case' 0 CA--C 1.538 0.486 0 CA-C-O 119.269 -0.396 . . . . 4.0300000000000002 111.821 -179.509 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' HZP . . . . . 0.598 ' HDA' ' N ' ' A' ' 10' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 162.37 145.54 4.37 Favored Glycine 0 N--CA 1.444 -0.827 0 C-N-CA 120.855 -0.688 . . . . 2.0600000000000001 112.433 177.246 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 8.0 p -99.47 -28.43 3.44 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-O 121.387 0.613 . . . . 4.7699999999999996 109.539 174.829 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -135.66 0.72 3.46 Favored Glycine 0 N--CA 1.448 -0.508 0 CA-C-N 115.498 -0.774 . . . . 3.8199999999999998 111.789 176.888 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 82.9 t60 . . . . . 0 C--O 1.245 0.832 0 CA-C-O 118.439 -0.791 . . . . 6.0599999999999996 109.874 179.712 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 2' ' ' PHE . . . . . 0.497 ' HB3' ' OG1' ' A' ' 5' ' ' THR . 98.8 m-85 . . . . . 0 N--CA 1.454 -0.266 0 CA-C-O 121.223 0.535 . . . . 3.2599999999999998 109.928 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 51.4 mtm180 . . . . . 0 C--N 1.323 -0.558 0 CA-C-N 115.417 -0.81 . . . . 4.7400000000000002 112.574 -175.434 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 5' ' ' THR . . . . . 0.497 ' OG1' ' HB3' ' A' ' 2' ' ' PHE . 14.6 m . . . . . 0 N--CA 1.449 -0.479 0 N-CA-C 109.777 -0.453 . . . . 1.8700000000000001 109.777 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . 56.36 69.26 1.86 Allowed Pre-proline 0 C--N 1.331 -0.21 0 CA-C-N 115.391 -0.822 . . . . 1.28 109.608 -171.592 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 14.6 Cg_endo -55.99 93.85 0.05 OUTLIER 'Trans proline' 0 C--N 1.348 0.53 0 C-N-CA 123.325 2.683 . . . . 2.4199999999999999 113.339 -173.261 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -98.59 -139.97 11.15 Favored Glycine 0 N--CA 1.446 -0.651 0 C-N-CA 120.769 -0.729 . . . . 1.73 112.74 179.081 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' HIS . . . . . 0.586 ' O ' ' HA ' ' A' ' 13' ' ' VAL . 74.9 t60 -70.25 -43.35 70.71 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 111.594 0.22 . . . . 4.2999999999999998 111.594 -173.695 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 18.0 m . . . . . 0 C--N 1.322 -0.595 0 N-CA-C 112.027 0.381 . . . . 3.75 112.027 179.618 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.339 0 N-CA-C 112.652 -0.179 . . . . 2.0600000000000001 112.652 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.586 ' HA ' ' O ' ' A' ' 9' ' ' HIS . 7.2 t 57.8 43.12 0.3 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.355 0 CA-C-O 121.778 0.799 . . . . 4.25 109.982 -177.004 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 81.1 14.15 79.72 Favored Glycine 0 N--CA 1.449 -0.449 0 CA-C-N 115.6 -0.727 . . . . 3.8199999999999998 112.626 -179.934 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 47.1 t-80 . . . . . 0 C--O 1.247 0.961 0 CA-C-O 118.736 -0.649 . . . . 5.3099999999999996 110.106 178.38 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 80.9 m-85 . . . . . 0 C--O 1.231 0.082 0 CA-C-O 120.648 0.261 . . . . 3.2599999999999998 110.602 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 65.2 mtm180 . . . . . 0 C--N 1.319 -0.748 0 CA-C-N 116.306 -0.407 . . . . 4.7400000000000002 111.672 179.304 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 50.6 m . . . . . 0 N--CA 1.457 -0.12 0 N-CA-C 110.515 -0.18 . . . . 1.8700000000000001 110.515 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . 50.42 63.28 10.24 Favored Pre-proline 0 N--CA 1.463 0.216 0 O-C-N 123.796 0.685 . . . . 1.28 109.841 -173.855 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.439 ' HB2' ' HA ' ' A' ' 15' ' ' HIS . 11.0 Cg_exo -68.68 107.24 1.61 Allowed 'Trans proline' 0 N--CA 1.46 -0.499 0 C-N-CA 122.753 2.302 . . . . 2.4199999999999999 113.291 -168.718 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -101.47 -142.42 12.69 Favored Glycine 0 N--CA 1.445 -0.709 0 CA-C-N 115.685 -0.689 . . . . 1.73 112.135 175.833 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' HIS . . . . . 0.409 ' O ' ' HA ' ' A' ' 13' ' ' VAL . 33.3 m80 -66.79 -40.05 88.0 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 111.883 0.327 . . . . 4.2999999999999998 111.883 -176.145 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 51.9 m . . . . . 0 CA--C 1.54 0.564 0 N-CA-C 112.03 0.382 . . . . 3.75 112.03 -178.645 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.362 0 CA-C-O 120.152 -0.249 . . . . 2.0600000000000001 112.972 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.409 ' HA ' ' O ' ' A' ' 9' ' ' HIS . 7.7 t 55.34 42.02 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.462 0.162 0 CA-C-O 122.121 0.963 . . . . 4.25 108.903 -175.682 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.472 ' O ' ' HB2' ' A' ' 15' ' ' HIS . . . 128.49 -52.31 0.83 Allowed Glycine 0 N--CA 1.442 -0.91 0 CA-C-N 114.861 -1.063 . . . . 3.8199999999999998 110.869 -174.387 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 15' ' ' HIS . . . . . 0.472 ' HB2' ' O ' ' A' ' 14' ' ' GLY . 38.7 t-80 . . . . . 0 C--O 1.245 0.84 0 C-N-CA 123.513 0.725 . . . . 5.3099999999999996 109.478 178.932 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 2' ' ' PHE . . . . . 0.475 ' HB3' ' HB ' ' A' ' 5' ' ' THR . 94.3 m-85 . . . . . 0 N--CA 1.464 0.235 0 CA-C-O 120.973 0.416 . . . . 3.2599999999999998 110.9 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 41.0 mtp180 . . . . . 0 C--N 1.325 -0.457 0 CA-C-N 115.762 -0.653 . . . . 4.7400000000000002 112.428 -176.763 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 5' ' ' THR . . . . . 0.475 ' HB ' ' HB3' ' A' ' 2' ' ' PHE . 8.4 m . . . . . 0 N--CA 1.454 -0.236 0 N-CA-C 110.346 -0.242 . . . . 1.8700000000000001 110.346 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . 51.0 64.09 8.75 Favored Pre-proline 0 C--O 1.234 0.26 0 N-CA-C 109.554 -0.536 . . . . 1.28 109.554 -173.627 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -57.64 97.62 0.08 OUTLIER 'Trans proline' 0 C--N 1.345 0.375 0 C-N-CA 123.597 2.865 . . . . 2.4199999999999999 113.738 -167.525 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -95.72 -150.09 26.55 Favored Glycine 0 N--CA 1.445 -0.704 0 CA-C-N 115.566 -0.743 . . . . 1.73 111.765 174.952 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 86.1 t60 -73.25 -43.31 61.35 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 120.598 0.237 . . . . 4.2999999999999998 111.452 -176.083 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 48.4 m . . . . . 0 C--N 1.323 -0.565 0 N-CA-C 111.949 0.352 . . . . 3.75 111.949 -179.297 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.823 0 N-CA-C 112.369 -0.292 . . . . 2.0600000000000001 112.369 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 40.3 t -59.63 -32.6 49.57 Favored 'Isoleucine or valine' 0 C--O 1.234 0.258 0 CA-C-O 121.329 0.585 . . . . 4.25 110.07 178.029 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -112.58 23.88 14.53 Favored Glycine 0 N--CA 1.447 -0.577 0 N-CA-C 111.062 -0.815 . . . . 3.8199999999999998 111.062 173.467 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 6.8 t60 . . . . . 0 C--O 1.248 0.99 0 CA-C-O 118.287 -0.864 . . . . 5.3099999999999996 110.16 -178.505 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 29.6 p90 . . . . . 0 N--CA 1.458 -0.039 0 CA-C-O 121.387 0.613 . . . . 3.2599999999999998 110.661 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 18.2 mtp180 . . . . . 0 C--N 1.322 -0.617 0 CA-C-N 115.934 -0.575 . . . . 4.7400000000000002 112.32 -178.969 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 40.9 p . . . . . 0 N--CA 1.454 -0.229 0 CA-C-O 120.905 0.383 . . . . 1.8700000000000001 110.177 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . 57.72 68.81 1.78 Allowed Pre-proline 0 N--CA 1.462 0.128 0 CA-C-N 115.475 -0.784 . . . . 1.28 109.806 -172.533 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_exo -56.25 99.73 0.08 OUTLIER 'Trans proline' 0 C--N 1.347 0.486 0 C-N-CA 123.616 2.877 . . . . 2.4199999999999999 113.756 -169.92 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -104.07 -130.77 6.97 Favored Glycine 0 N--CA 1.442 -0.906 0 CA-C-N 115.634 -0.712 . . . . 1.73 111.73 174.658 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 39.7 m80 -86.26 -59.14 2.37 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.882 0.372 . . . . 4.2999999999999998 110.719 -176.465 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 55.9 m . . . . . 0 CA--C 1.539 0.535 0 N-CA-C 112.572 0.582 . . . . 3.75 112.572 -178.588 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.457 ' HA3' ' O ' ' A' ' 15' ' ' HIS . . . . . . . . 0 C--O 1.23 -0.123 0 CA-C-O 120.007 -0.329 . . . . 2.0600000000000001 113.667 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 6.3 t 53.24 42.62 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.331 0 CA-C-O 121.83 0.824 . . . . 4.25 109.622 -175.778 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 112.12 -29.66 8.24 Favored Glycine 0 N--CA 1.447 -0.602 0 CA-C-N 115.59 -0.732 . . . . 3.8199999999999998 112.456 -177.213 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' HIS . . . . . 0.457 ' O ' ' HA3' ' A' ' 12' ' ' GLY . 83.3 t60 . . . . . 0 C--O 1.246 0.891 0 CA-C-O 118.905 -0.569 . . . . 5.3099999999999996 109.95 -178.58 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 92.1 m-85 . . . . . 0 C--O 1.232 0.176 0 CA-C-O 121.198 0.523 . . . . 3.2599999999999998 110.103 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 65.1 mtp180 . . . . . 0 C--N 1.322 -0.598 0 N-CA-C 112.933 0.716 . . . . 4.7400000000000002 112.933 -175.875 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 22.7 p . . . . . 0 C--O 1.234 0.257 0 N-CA-C 110.79 -0.078 . . . . 1.8700000000000001 110.79 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . 55.98 74.57 0.68 Allowed Pre-proline 0 C--O 1.232 0.172 0 O-C-N 123.811 0.694 . . . . 1.28 110.646 -177.013 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_exo -51.56 94.38 0.03 OUTLIER 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 124.12 3.214 . . . . 2.4199999999999999 114.144 -174.836 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -89.76 -164.97 40.46 Favored Glycine 0 N--CA 1.445 -0.714 0 N-CA-C 111.432 -0.667 . . . . 1.73 111.432 172.456 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' HIS . . . . . 0.598 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 55.5 t-80 -67.82 -25.43 65.56 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.798 0.333 . . . . 4.2999999999999998 111.049 -178.255 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 45.3 t . . . . . 0 CA--C 1.54 0.571 0 CA-C-O 119.374 -0.346 . . . . 3.75 111.383 177.429 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.445 -0.762 0 N-CA-C 112.36 -0.296 . . . . 2.0600000000000001 112.36 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.598 ' HB ' ' O ' ' A' ' 9' ' ' HIS . 7.3 p -60.57 -36.74 72.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-O 120.865 0.364 . . . . 4.25 110.858 177.575 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -115.09 -23.06 4.7 Favored Glycine 0 N--CA 1.446 -0.666 0 C-N-CA 120.771 -0.728 . . . . 3.8199999999999998 112.308 179.652 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 54.8 t-80 . . . . . 0 C--O 1.248 1.007 0 CA-C-O 118.48 -0.771 . . . . 5.3099999999999996 110.107 -179.664 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 66.3 m-85 . . . . . 0 N--CA 1.454 -0.249 0 N-CA-C 109.821 -0.437 . . . . 3.2599999999999998 109.821 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 . . . . . 0 C--N 1.322 -0.592 0 CA-C-O 118.986 -0.531 . . . . 4.7400000000000002 112.171 -176.296 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 96.8 m . . . . . 0 N--CA 1.454 -0.253 0 N-CA-C 108.814 -0.81 . . . . 1.8700000000000001 108.814 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . 57.25 73.69 0.75 Allowed Pre-proline 0 C--O 1.233 0.232 0 CA-C-O 121.252 0.549 . . . . 1.28 109.69 -174.093 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 25.0 Cg_exo -63.2 137.49 61.51 Favored 'Trans proline' 0 C--O 1.235 0.329 0 C-N-CA 123.426 2.75 . . . . 2.4199999999999999 113.395 -170.734 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -147.02 -70.69 0.01 OUTLIER Glycine 0 N--CA 1.446 -0.687 0 C-N-CA 120.889 -0.672 . . . . 1.73 112.739 177.807 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 85.4 t60 -87.53 -81.59 0.24 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.862 0.331 . . . . 4.2999999999999998 111.723 -174.737 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 5.3 p . . . . . 0 CA--C 1.54 0.575 0 N-CA-C 113.233 0.827 . . . . 3.75 113.233 -174.964 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.441 -0.973 0 N-CA-C 110.764 -0.934 . . . . 2.0600000000000001 110.764 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 7.7 p -88.34 -30.28 5.45 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 N-CA-C 109.419 -0.585 . . . . 4.25 109.419 173.822 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -148.46 14.61 1.24 Allowed Glycine 0 N--CA 1.448 -0.536 0 CA-C-N 115.606 -0.725 . . . . 3.8199999999999998 111.78 176.792 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 58.5 t-80 . . . . . 0 C--O 1.249 1.028 0 CA-C-O 118.453 -0.784 . . . . 5.3099999999999996 110.445 -178.15 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 99.0 m-85 . . . . . 0 N--CA 1.463 0.176 0 CA-C-O 121.214 0.53 . . . . 3.2599999999999998 110.393 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 73.7 mtm180 . . . . . 0 C--N 1.322 -0.591 0 N-CA-C 113.393 0.886 . . . . 4.7400000000000002 113.393 -176.023 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 9.2 m . . . . . 0 N--CA 1.452 -0.347 0 CA-C-O 120.471 0.177 . . . . 1.8700000000000001 111.065 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . 57.75 73.62 0.74 Allowed Pre-proline 0 N--CA 1.466 0.35 0 CA-C-N 115.991 -0.55 . . . . 1.28 112.106 179.042 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.618 ' HB3' ' H ' ' A' ' 13' ' ' VAL . 6.0 Cg_endo -49.04 143.92 17.03 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 123.622 2.882 . . . . 2.4199999999999999 113.558 179.472 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 179.22 -112.88 0.38 Allowed Glycine 0 N--CA 1.446 -0.691 0 C-N-CA 120.74 -0.743 . . . . 1.73 112.671 176.982 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 16.4 t60 -82.01 -70.87 0.51 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.571 0.185 . . . . 4.2999999999999998 110.881 -177.581 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 19.1 t . . . . . 0 CA--C 1.537 0.461 0 C-N-CA 120.756 -0.378 . . . . 3.75 110.247 176.9 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.698 0 N-CA-C 112.802 -0.119 . . . . 2.0600000000000001 112.802 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.618 ' H ' ' HB3' ' A' ' 7' ' ' PRO . 52.3 t -67.75 -41.23 85.06 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-O 121.068 0.461 . . . . 4.25 110.11 177.222 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -126.89 18.6 6.23 Favored Glycine 0 N--CA 1.448 -0.517 0 C-N-CA 121.04 -0.6 . . . . 3.8199999999999998 111.622 175.963 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 9.4 t60 . . . . . 0 C--O 1.243 0.753 0 CA-C-O 118.44 -0.79 . . . . 5.3099999999999996 109.891 -176.775 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 84.4 m-85 . . . . . 0 N--CA 1.464 0.273 0 CA-C-O 121.184 0.516 . . . . 3.2599999999999998 110.831 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 3' ' ' ARG . . . . . 0.643 ' O ' ' HG3' ' A' ' 7' ' ' PRO . 99.5 mtt180 . . . . . 0 CA--C 1.539 0.546 0 CA-C-N 115.726 -0.67 . . . . 4.7400000000000002 112.552 -176.8 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 3.9 t . . . . . 0 N--CA 1.453 -0.278 0 CA-C-O 121.42 0.629 . . . . 1.8700000000000001 111.803 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . 52.29 73.59 0.93 Allowed Pre-proline 0 C--N 1.33 -0.256 0 CA-C-N 115.07 -0.968 . . . . 1.28 112.507 177.752 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.643 ' HG3' ' O ' ' A' ' 3' ' ' ARG . 5.9 Cg_endo -84.6 -53.65 0.03 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.616 0 C-N-CA 123.17 2.58 . . . . 2.4199999999999999 111.069 177.367 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -143.96 68.58 0.42 Allowed Glycine 0 N--CA 1.443 -0.858 0 N-CA-C 109.985 -1.246 . . . . 1.73 109.985 174.916 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 99.5 m-70 71.67 -61.7 0.48 Allowed 'General case' 0 N--CA 1.468 0.454 0 C-N-CA 123.571 0.748 . . . . 4.2999999999999998 110.805 -173.947 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 26.1 m . . . . . 0 C--N 1.325 -0.492 0 CA-C-N 116.677 -0.238 . . . . 3.75 110.8 179.636 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.471 0 N-CA-C 112.159 -0.376 . . . . 2.0600000000000001 112.159 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 6.3 m -67.95 83.1 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-O 121.666 0.746 . . . . 4.25 110.049 172.747 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 130.99 -15.93 5.33 Favored Glycine 0 N--CA 1.445 -0.76 0 CA-C-N 115.39 -0.823 . . . . 3.8199999999999998 111.354 -174.003 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 73.3 t60 . . . . . 0 C--O 1.245 0.817 0 CA-C-O 118.758 -0.639 . . . . 5.3099999999999996 109.579 178.091 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 76.5 m-85 . . . . . 0 N--CA 1.454 -0.268 0 CA-C-O 120.942 0.401 . . . . 3.2599999999999998 110.512 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 84.1 mtt180 . . . . . 0 C--N 1.321 -0.665 0 CA-C-O 119.086 -0.483 . . . . 4.7400000000000002 111.684 176.631 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 10.9 p . . . . . 0 C--O 1.235 0.293 0 N-CA-C 109.741 -0.466 . . . . 1.8700000000000001 109.741 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . 66.23 94.91 0.05 OUTLIER Pre-proline 0 C--N 1.333 -0.137 0 CA-C-N 115.52 -0.764 . . . . 1.28 110.754 -177.725 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_exo -64.88 102.92 0.44 Allowed 'Trans proline' 0 C--O 1.232 0.222 0 C-N-CA 122.702 2.268 . . . . 2.4199999999999999 112.31 -179.417 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -160.98 51.52 0.34 Allowed Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 120.901 -0.666 . . . . 1.73 112.223 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 40.4 t-80 -174.23 -47.35 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.23 0.538 . . . . 4.2999999999999998 109.73 -179.421 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 23.3 t . . . . . 0 C--N 1.323 -0.564 0 CA-C-N 115.345 -0.843 . . . . 3.75 110.259 -177.147 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.808 0 N-CA-C 112.255 -0.338 . . . . 2.0600000000000001 112.255 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 73.4 t -62.2 -52.95 54.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 N-CA-C 109.414 -0.587 . . . . 4.25 109.414 178.478 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -107.04 23.41 27.51 Favored Glycine 0 N--CA 1.443 -0.863 0 N-CA-C 110.782 -0.927 . . . . 3.8199999999999998 110.782 172.773 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 41.9 m80 . . . . . 0 C--O 1.25 1.089 0 CA-C-N 115.089 -0.556 . . . . 5.3099999999999996 110.403 -176.476 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 75.5 m-85 . . . . . 0 N--CA 1.453 -0.283 0 CA-C-O 121.19 0.519 . . . . 3.2599999999999998 109.726 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 3' ' ' ARG . . . . . 0.402 HH11 ' HD3' ' A' ' 3' ' ' ARG . 47.6 mtm-85 . . . . . 0 C--N 1.325 -0.488 0 CA-C-N 115.842 -0.617 . . . . 4.7400000000000002 111.964 -176.162 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 8.9 t . . . . . 0 N--CA 1.449 -0.51 0 N-CA-C 108.442 -0.947 . . . . 1.8700000000000001 108.442 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . 50.65 63.19 10.31 Favored Pre-proline 0 CA--C 1.531 0.232 0 N-CA-C 109.757 -0.46 . . . . 1.28 109.757 -170.679 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -59.65 140.68 94.79 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 123.237 2.625 . . . . 2.4199999999999999 113.26 -170.953 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -144.91 -53.41 0.03 OUTLIER Glycine 0 N--CA 1.448 -0.558 0 C-N-CA 120.766 -0.73 . . . . 1.73 112.473 178.866 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 60.1 m80 -97.02 -105.56 0.17 Allowed 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.653 0.263 . . . . 4.2999999999999998 111.349 -178.495 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 47.0 t . . . . . 0 CA--C 1.538 0.486 0 CA-C-O 119.269 -0.396 . . . . 3.75 111.821 -179.509 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.827 0 N-CA-C 112.433 -0.267 . . . . 2.0600000000000001 112.433 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 8.0 p -99.47 -28.43 3.44 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-O 121.387 0.613 . . . . 4.25 109.539 174.829 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -135.66 0.72 3.46 Favored Glycine 0 N--CA 1.448 -0.508 0 CA-C-N 115.498 -0.774 . . . . 3.8199999999999998 111.789 176.888 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 82.9 t60 . . . . . 0 C--O 1.245 0.832 0 CA-C-O 118.439 -0.791 . . . . 5.3099999999999996 109.874 179.712 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 0.983 0 CA-C-O 120.696 0.284 . . . . 4.0199999999999996 110.357 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' PHE . . . . . 0.497 ' HB3' ' OG1' ' A' ' 5' ' ' THR . 98.8 m-85 -99.38 88.98 4.03 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 121.223 0.535 . . . . 3.2599999999999998 109.928 179.259 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 3' ' ' ARG . . . . . 0.465 ' HB2' ' HDA' ' A' ' 4' ' ' HZP . 51.4 mtm180 -68.32 -52.22 35.93 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.417 -0.81 . . . . 4.7400000000000002 112.574 -175.434 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' HZP . . . . . 0.465 ' HDA' ' HB2' ' A' ' 3' ' ' ARG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.497 ' OG1' ' HB3' ' A' ' 2' ' ' PHE . 14.6 m -98.62 90.87 4.88 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 109.777 -0.453 . . . . 1.8700000000000001 109.777 -175.667 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . 56.36 69.26 1.86 Allowed Pre-proline 0 C--N 1.331 -0.21 0 CA-C-N 115.391 -0.822 . . . . 1.28 109.608 -171.592 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.526 ' HA ' ' HBA' ' A' ' 11' ' ' HZP . 14.6 Cg_endo -55.99 93.85 0.05 OUTLIER 'Trans proline' 0 C--N 1.348 0.53 0 C-N-CA 123.325 2.683 . . . . 2.4199999999999999 113.339 -173.261 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -98.59 -139.97 11.15 Favored Glycine 0 N--CA 1.446 -0.651 0 C-N-CA 120.769 -0.729 . . . . 1.73 112.74 179.081 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' HIS . . . . . 0.586 ' O ' ' HA ' ' A' ' 13' ' ' VAL . 74.9 t60 -70.25 -43.35 70.71 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 111.594 0.22 . . . . 4.2999999999999998 111.594 -173.695 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.495 ' HB2' ' HDA' ' A' ' 11' ' ' HZP . 18.0 m -93.62 -49.63 5.78 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 112.027 0.381 . . . . 3.75 112.027 179.618 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' HZP . . . . . 0.526 ' HBA' ' HA ' ' A' ' 7' ' ' PRO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -96.74 -5.56 58.64 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.587 -0.816 . . . . 2.0600000000000001 112.652 -176.852 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.586 ' HA ' ' O ' ' A' ' 9' ' ' HIS . 7.2 t 57.8 43.12 0.3 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.355 0 CA-C-O 121.778 0.799 . . . . 4.25 109.982 -177.004 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 81.1 14.15 79.72 Favored Glycine 0 N--CA 1.449 -0.449 0 CA-C-N 115.6 -0.727 . . . . 3.8199999999999998 112.626 -179.934 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 47.1 t-80 . . . . . 0 C--O 1.247 0.961 0 CA-C-O 118.736 -0.649 . . . . 5.3099999999999996 110.106 178.38 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.069 0 CA-C-O 120.609 0.243 . . . . 4.0199999999999996 110.928 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 80.9 m-85 -83.76 160.92 21.15 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.648 0.261 . . . . 3.2599999999999998 110.602 -179.352 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' ARG . . . . . 0.514 ' HB2' ' HDA' ' A' ' 4' ' ' HZP . 65.2 mtm180 -72.87 -53.1 12.28 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 116.306 -0.407 . . . . 4.7400000000000002 111.672 179.304 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' HZP . . . . . 0.514 ' HDA' ' HB2' ' A' ' 3' ' ' ARG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 50.6 m -127.06 107.82 10.38 Favored 'General case' 0 C--N 1.326 -0.442 0 C-N-CA 120.967 -0.293 . . . . 1.8700000000000001 110.515 -177.906 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . 50.42 63.28 10.24 Favored Pre-proline 0 N--CA 1.463 0.216 0 O-C-N 123.796 0.685 . . . . 1.28 109.841 -173.855 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.57 ' HA ' ' HBA' ' A' ' 11' ' ' HZP . 11.0 Cg_exo -68.68 107.24 1.61 Allowed 'Trans proline' 0 N--CA 1.46 -0.499 0 C-N-CA 122.753 2.302 . . . . 2.4199999999999999 113.291 -168.718 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -101.47 -142.42 12.69 Favored Glycine 0 N--CA 1.445 -0.709 0 CA-C-N 115.685 -0.689 . . . . 1.73 112.135 175.833 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' HIS . . . . . 0.409 ' O ' ' HA ' ' A' ' 13' ' ' VAL . 33.3 m80 -66.79 -40.05 88.0 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 111.883 0.327 . . . . 4.2999999999999998 111.883 -176.145 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.561 ' HB2' ' HDA' ' A' ' 11' ' ' HZP . 51.9 m -85.72 -55.44 3.98 Favored 'General case' 0 CA--C 1.54 0.564 0 N-CA-C 112.03 0.382 . . . . 3.75 112.03 -178.645 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' HZP . . . . . 0.57 ' HBA' ' HA ' ' A' ' 7' ' ' PRO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -91.91 6.16 79.25 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.784 -0.722 . . . . 2.0600000000000001 112.972 -177.144 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.409 ' HA ' ' O ' ' A' ' 9' ' ' HIS . 7.7 t 55.34 42.02 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.462 0.162 0 CA-C-O 122.121 0.963 . . . . 4.25 108.903 -175.682 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.472 ' O ' ' HB2' ' A' ' 15' ' ' HIS . . . 128.49 -52.31 0.83 Allowed Glycine 0 N--CA 1.442 -0.91 0 CA-C-N 114.861 -1.063 . . . . 3.8199999999999998 110.869 -174.387 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' HIS . . . . . 0.472 ' HB2' ' O ' ' A' ' 14' ' ' GLY . 38.7 t-80 . . . . . 0 C--O 1.245 0.84 0 C-N-CA 123.513 0.725 . . . . 5.3099999999999996 109.478 178.932 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.012 0 N-CA-C 110.221 -0.288 . . . . 4.0199999999999996 110.221 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' PHE . . . . . 0.475 ' HB3' ' HB ' ' A' ' 5' ' ' THR . 94.3 m-85 60.11 65.17 1.13 Allowed 'General case' 0 N--CA 1.464 0.235 0 O-C-N 123.476 0.485 . . . . 3.2599999999999998 110.9 179.566 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 3' ' ' ARG . . . . . 0.423 ' HB2' ' HDA' ' A' ' 4' ' ' HZP . 41.0 mtp180 -70.4 -50.35 39.49 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.762 -0.653 . . . . 4.7400000000000002 112.428 -176.763 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' HZP . . . . . 0.423 ' HDA' ' HB2' ' A' ' 3' ' ' ARG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.475 ' HB ' ' HB3' ' A' ' 2' ' ' PHE . 8.4 m -94.85 102.02 13.85 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.617 -0.265 . . . . 1.8700000000000001 110.346 -173.903 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . 51.0 64.09 8.75 Favored Pre-proline 0 C--O 1.234 0.26 0 N-CA-C 109.554 -0.536 . . . . 1.28 109.554 -173.627 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -57.64 97.62 0.08 OUTLIER 'Trans proline' 0 C--N 1.345 0.375 0 C-N-CA 123.597 2.865 . . . . 2.4199999999999999 113.738 -167.525 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -95.72 -150.09 26.55 Favored Glycine 0 N--CA 1.445 -0.704 0 CA-C-N 115.566 -0.743 . . . . 1.73 111.765 174.952 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 86.1 t60 -73.25 -43.31 61.35 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 120.598 0.237 . . . . 4.2999999999999998 111.452 -176.083 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.524 ' HB2' ' HDA' ' A' ' 11' ' ' HZP . 48.4 m -78.94 -48.3 14.79 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 111.949 0.352 . . . . 3.75 111.949 -179.297 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' HZP . . . . . 0.524 ' HDA' ' HB2' ' A' ' 10' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 140.93 103.39 0.52 Allowed Glycine 0 N--CA 1.444 -0.823 0 C-N-CA 120.951 -0.642 . . . . 2.0600000000000001 112.369 175.988 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 40.3 t -59.63 -32.6 49.57 Favored 'Isoleucine or valine' 0 C--O 1.234 0.258 0 CA-C-O 121.329 0.585 . . . . 4.25 110.07 178.029 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -112.58 23.88 14.53 Favored Glycine 0 N--CA 1.447 -0.577 0 N-CA-C 111.062 -0.815 . . . . 3.8199999999999998 111.062 173.467 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 6.8 t60 . . . . . 0 C--O 1.248 0.99 0 CA-C-O 118.287 -0.864 . . . . 5.3099999999999996 110.16 -178.505 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.949 0 CA-C-O 120.551 0.215 . . . . 4.0199999999999996 110.752 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' PHE . . . . . 0.564 ' O ' ' HB ' ' A' ' 11' ' ' HZP . 29.6 p90 -137.07 38.41 2.55 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.387 0.613 . . . . 3.2599999999999998 110.661 -179.059 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 3' ' ' ARG . . . . . 0.524 ' HG2' ' O ' ' A' ' 11' ' ' HZP . 18.2 mtp180 -64.62 -50.5 66.91 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.934 -0.575 . . . . 4.7400000000000002 112.32 -178.969 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 4' ' ' HZP . . . . . 0.472 ' HA ' ' HG3' ' A' ' 7' ' ' PRO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 40.9 p -90.36 82.52 5.94 Favored 'General case' 0 C--N 1.326 -0.429 0 C-N-CA 120.437 -0.505 . . . . 1.8700000000000001 110.177 -179.778 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . 57.72 68.81 1.78 Allowed Pre-proline 0 N--CA 1.462 0.128 0 CA-C-N 115.475 -0.784 . . . . 1.28 109.806 -172.533 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.472 ' HG3' ' HA ' ' A' ' 4' ' ' HZP . 37.0 Cg_exo -56.25 99.73 0.08 OUTLIER 'Trans proline' 0 C--N 1.347 0.486 0 C-N-CA 123.616 2.877 . . . . 2.4199999999999999 113.756 -169.92 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -104.07 -130.77 6.97 Favored Glycine 0 N--CA 1.442 -0.906 0 CA-C-N 115.634 -0.712 . . . . 1.73 111.73 174.658 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 39.7 m80 -86.26 -59.14 2.37 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.882 0.372 . . . . 4.2999999999999998 110.719 -176.465 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.497 ' HB2' ' HDA' ' A' ' 11' ' ' HZP . 55.9 m -62.4 -48.75 78.34 Favored 'General case' 0 CA--C 1.539 0.535 0 N-CA-C 112.572 0.582 . . . . 3.75 112.572 -178.588 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' HZP . . . . . 0.564 ' HB ' ' O ' ' A' ' 2' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.457 ' HA3' ' O ' ' A' ' 15' ' ' HIS . . . -132.9 15.99 4.79 Favored Glycine 0 C--N 1.329 0.149 0 C-N-CA 119.705 -1.235 . . . . 2.0600000000000001 113.667 -176.201 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 6.3 t 53.24 42.62 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.331 0 CA-C-O 121.83 0.824 . . . . 4.25 109.622 -175.778 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 112.12 -29.66 8.24 Favored Glycine 0 N--CA 1.447 -0.602 0 CA-C-N 115.59 -0.732 . . . . 3.8199999999999998 112.456 -177.213 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' HIS . . . . . 0.457 ' O ' ' HA3' ' A' ' 12' ' ' GLY . 83.3 t60 . . . . . 0 C--O 1.246 0.891 0 CA-C-O 118.905 -0.569 . . . . 5.3099999999999996 109.95 -178.58 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.936 0 N-CA-C 110.28 -0.267 . . . . 4.0199999999999996 110.28 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 92.1 m-85 -72.33 122.19 20.73 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 121.198 0.523 . . . . 3.2599999999999998 110.103 178.166 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' ARG . . . . . 0.46 ' N ' ' HD ' ' A' ' 4' ' ' HZP . 65.1 mtp180 -80.04 -47.82 14.28 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 112.933 0.716 . . . . 4.7400000000000002 112.933 -175.875 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 4' ' ' HZP . . . . . 0.46 ' HD ' ' N ' ' A' ' 3' ' ' ARG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 22.7 p -114.26 110.94 20.72 Favored 'General case' 0 C--N 1.323 -0.552 0 O-C-N 122.364 -0.21 . . . . 1.8700000000000001 110.79 -177.778 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . 55.98 74.57 0.68 Allowed Pre-proline 0 C--O 1.232 0.172 0 O-C-N 123.811 0.694 . . . . 1.28 110.646 -177.013 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_exo -51.56 94.38 0.03 OUTLIER 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 124.12 3.214 . . . . 2.4199999999999999 114.144 -174.836 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -89.76 -164.97 40.46 Favored Glycine 0 N--CA 1.445 -0.714 0 N-CA-C 111.432 -0.667 . . . . 1.73 111.432 172.456 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' HIS . . . . . 0.598 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 55.5 t-80 -67.82 -25.43 65.56 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.798 0.333 . . . . 4.2999999999999998 111.049 -178.255 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.559 ' HB3' ' HDA' ' A' ' 11' ' ' HZP . 45.3 t -101.9 -53.14 3.01 Favored 'General case' 0 CA--C 1.54 0.571 0 CA-C-O 119.374 -0.346 . . . . 3.75 111.383 177.429 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' HZP . . . . . 0.559 ' HDA' ' HB3' ' A' ' 10' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -140.68 58.99 0.57 Allowed Glycine 0 N--CA 1.445 -0.762 0 C-N-CA 120.491 -0.861 . . . . 2.0600000000000001 112.36 -175.257 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.598 ' HB ' ' O ' ' A' ' 9' ' ' HIS . 7.3 p -60.57 -36.74 72.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-O 120.865 0.364 . . . . 4.25 110.858 177.575 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -115.09 -23.06 4.7 Favored Glycine 0 N--CA 1.446 -0.666 0 C-N-CA 120.771 -0.728 . . . . 3.8199999999999998 112.308 179.652 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 54.8 t-80 . . . . . 0 C--O 1.248 1.007 0 CA-C-O 118.48 -0.771 . . . . 5.3099999999999996 110.107 -179.664 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.039 0 CA-C-O 120.605 0.241 . . . . 4.0199999999999996 110.648 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 66.3 m-85 -89.86 174.64 7.58 Favored 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 109.821 -0.437 . . . . 3.2599999999999998 109.821 174.415 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' ARG . . . . . 0.617 ' O ' ' HG ' ' A' ' 11' ' ' HZP . 99.8 mtt180 -68.11 -63.39 1.07 Allowed 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 118.986 -0.531 . . . . 4.7400000000000002 112.171 -176.296 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 4' ' ' HZP . . . . . 0.467 ' HDA' ' HB2' ' A' ' 3' ' ' ARG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 96.8 m -162.12 125.28 3.01 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 108.814 -0.81 . . . . 1.8700000000000001 108.814 -177.755 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . 57.25 73.69 0.75 Allowed Pre-proline 0 C--O 1.233 0.232 0 CA-C-O 121.252 0.549 . . . . 1.28 109.69 -174.093 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 25.0 Cg_exo -63.2 137.49 61.51 Favored 'Trans proline' 0 C--O 1.235 0.329 0 C-N-CA 123.426 2.75 . . . . 2.4199999999999999 113.395 -170.734 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -147.02 -70.69 0.01 OUTLIER Glycine 0 N--CA 1.446 -0.687 0 C-N-CA 120.889 -0.672 . . . . 1.73 112.739 177.807 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 85.4 t60 -87.53 -81.59 0.24 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.862 0.331 . . . . 4.2999999999999998 111.723 -174.737 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.607 ' N ' ' HD ' ' A' ' 11' ' ' HZP . 5.3 p -90.3 -42.32 11.04 Favored 'General case' 0 CA--C 1.54 0.575 0 N-CA-C 113.233 0.827 . . . . 3.75 113.233 -174.964 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' HZP . . . . . 0.617 ' HG ' ' O ' ' A' ' 3' ' ' ARG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 160.38 -177.13 36.94 Favored Glycine 0 N--CA 1.441 -0.973 0 CA-C-N 114.528 -1.215 . . . . 2.0600000000000001 110.764 176.356 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 7.7 p -88.34 -30.28 5.45 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 N-CA-C 109.419 -0.585 . . . . 4.25 109.419 173.822 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -148.46 14.61 1.24 Allowed Glycine 0 N--CA 1.448 -0.536 0 CA-C-N 115.606 -0.725 . . . . 3.8199999999999998 111.78 176.792 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 58.5 t-80 . . . . . 0 C--O 1.249 1.028 0 CA-C-O 118.453 -0.784 . . . . 5.3099999999999996 110.445 -178.15 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.115 0 N-CA-C 110.451 -0.203 . . . . 4.0199999999999996 110.451 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 99.0 m-85 55.84 65.25 1.5 Allowed 'General case' 0 N--CA 1.463 0.176 0 CA-C-O 121.214 0.53 . . . . 3.2599999999999998 110.393 -179.441 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' ARG . . . . . 0.526 ' N ' ' HD ' ' A' ' 4' ' ' HZP . 73.7 mtm180 -64.62 -44.09 91.68 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 113.393 0.886 . . . . 4.7400000000000002 113.393 -176.023 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' HZP . . . . . 0.526 ' HD ' ' N ' ' A' ' 3' ' ' ARG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 9.2 m -126.64 112.88 15.99 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 120.471 0.177 . . . . 1.8700000000000001 111.065 -177.537 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . 57.75 73.62 0.74 Allowed Pre-proline 0 N--CA 1.466 0.35 0 CA-C-N 115.991 -0.55 . . . . 1.28 112.106 179.042 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.618 ' HB3' ' H ' ' A' ' 13' ' ' VAL . 6.0 Cg_endo -49.04 143.92 17.03 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 123.622 2.882 . . . . 2.4199999999999999 113.558 179.472 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 179.22 -112.88 0.38 Allowed Glycine 0 N--CA 1.446 -0.691 0 C-N-CA 120.74 -0.743 . . . . 1.73 112.671 176.982 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 16.4 t60 -82.01 -70.87 0.51 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.571 0.185 . . . . 4.2999999999999998 110.881 -177.581 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.624 ' HB3' ' HDA' ' A' ' 11' ' ' HZP . 19.1 t -71.51 -52.42 18.41 Favored 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 120.756 -0.378 . . . . 3.75 110.247 176.9 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' HZP . . . . . 0.624 ' HDA' ' HB3' ' A' ' 10' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -164.2 68.07 0.21 Allowed Glycine 0 N--CA 1.446 -0.698 0 C-N-CA 119.724 -1.227 . . . . 2.0600000000000001 112.802 -175.595 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.618 ' H ' ' HB3' ' A' ' 7' ' ' PRO . 52.3 t -67.75 -41.23 85.06 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-O 121.068 0.461 . . . . 4.25 110.11 177.222 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -126.89 18.6 6.23 Favored Glycine 0 N--CA 1.448 -0.517 0 C-N-CA 121.04 -0.6 . . . . 3.8199999999999998 111.622 175.963 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 9.4 t60 . . . . . 0 C--O 1.243 0.753 0 CA-C-O 118.44 -0.79 . . . . 5.3099999999999996 109.891 -176.775 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.009 0 CA-C-O 120.264 0.078 . . . . 4.0199999999999996 110.965 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 84.4 m-85 58.38 49.17 11.24 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-O 121.184 0.516 . . . . 3.2599999999999998 110.831 -178.425 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' ARG . . . . . 0.643 ' O ' ' HG3' ' A' ' 7' ' ' PRO . 99.5 mtt180 -75.91 -45.54 34.73 Favored 'General case' 0 CA--C 1.539 0.546 0 CA-C-N 115.726 -0.67 . . . . 4.7400000000000002 112.552 -176.8 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' HZP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 3.9 t -140.89 77.66 1.61 Allowed 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.42 0.629 . . . . 1.8700000000000001 111.803 -174.579 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . 52.29 73.59 0.93 Allowed Pre-proline 0 C--N 1.33 -0.256 0 CA-C-N 115.07 -0.968 . . . . 1.28 112.507 177.752 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.643 ' HG3' ' O ' ' A' ' 3' ' ' ARG . 5.9 Cg_endo -84.6 -53.65 0.03 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.616 0 C-N-CA 123.17 2.58 . . . . 2.4199999999999999 111.069 177.367 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -143.96 68.58 0.42 Allowed Glycine 0 N--CA 1.443 -0.858 0 N-CA-C 109.985 -1.246 . . . . 1.73 109.985 174.916 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 99.5 m-70 71.67 -61.7 0.48 Allowed 'General case' 0 N--CA 1.468 0.454 0 C-N-CA 123.571 0.748 . . . . 4.2999999999999998 110.805 -173.947 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 26.1 m -95.7 122.56 38.59 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.677 -0.238 . . . . 3.75 110.8 179.636 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' HZP . . . . . 0.462 ' HA ' ' CD ' ' A' ' 7' ' ' PRO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -172.34 -19.33 0.02 OUTLIER Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 120.692 -0.766 . . . . 2.0600000000000001 112.159 -178.012 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 6.3 m -67.95 83.1 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-O 121.666 0.746 . . . . 4.25 110.049 172.747 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 130.99 -15.93 5.33 Favored Glycine 0 N--CA 1.445 -0.76 0 CA-C-N 115.39 -0.823 . . . . 3.8199999999999998 111.354 -174.003 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 73.3 t60 . . . . . 0 C--O 1.245 0.817 0 CA-C-O 118.758 -0.639 . . . . 5.3099999999999996 109.579 178.091 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.97 0 CA-C-O 120.975 0.417 . . . . 4.0199999999999996 110.493 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 76.5 m-85 -112.74 112.46 23.97 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.147 -0.479 . . . . 3.2599999999999998 110.512 179.352 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' ARG . . . . . 0.508 ' O ' ' HB ' ' A' ' 11' ' ' HZP . 84.1 mtt180 -82.66 -50.91 8.24 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 119.086 -0.483 . . . . 4.7400000000000002 111.684 176.631 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' HZP . . . . . 0.449 ' HD ' ' N ' ' A' ' 3' ' ' ARG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 10.9 p -143.85 84.83 1.8 Allowed 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 116.124 -0.489 . . . . 1.8700000000000001 109.741 177.456 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . 66.23 94.91 0.05 OUTLIER Pre-proline 0 C--N 1.333 -0.137 0 CA-C-N 115.52 -0.764 . . . . 1.28 110.754 -177.725 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_exo -64.88 102.92 0.44 Allowed 'Trans proline' 0 C--O 1.232 0.222 0 C-N-CA 122.702 2.268 . . . . 2.4199999999999999 112.31 -179.417 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -160.98 51.52 0.34 Allowed Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 120.901 -0.666 . . . . 1.73 112.223 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 40.4 t-80 -174.23 -47.35 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.23 0.538 . . . . 4.2999999999999998 109.73 -179.421 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.644 ' N ' ' HD ' ' A' ' 11' ' ' HZP . 23.3 t -167.04 -47.83 0.02 OUTLIER 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.345 -0.843 . . . . 3.75 110.259 -177.147 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' HZP . . . . . 0.644 ' HD ' ' N ' ' A' ' 10' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -146.83 46.09 0.75 Allowed Glycine 0 N--CA 1.444 -0.808 0 C-N-CA 120.542 -0.837 . . . . 2.0600000000000001 112.255 -177.573 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 73.4 t -62.2 -52.95 54.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 N-CA-C 109.414 -0.587 . . . . 4.25 109.414 178.478 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -107.04 23.41 27.51 Favored Glycine 0 N--CA 1.443 -0.863 0 N-CA-C 110.782 -0.927 . . . . 3.8199999999999998 110.782 172.773 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 41.9 m80 . . . . . 0 C--O 1.25 1.089 0 CA-C-N 115.089 -0.556 . . . . 5.3099999999999996 110.403 -176.476 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.968 0 CA-C-O 121.011 0.434 . . . . 4.0199999999999996 110.758 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 75.5 m-85 -133.44 65.48 1.58 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.19 0.519 . . . . 3.2599999999999998 109.726 176.584 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' ARG . . . . . 0.519 ' HB2' ' HDA' ' A' ' 4' ' ' HZP . 47.6 mtm-85 -87.97 -57.51 2.91 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.842 -0.617 . . . . 4.7400000000000002 111.964 -176.162 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 4' ' ' HZP . . . . . 0.519 ' HDA' ' HB2' ' A' ' 3' ' ' ARG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 8.9 t -158.86 132.52 7.48 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 108.442 -0.947 . . . . 1.8700000000000001 108.442 177.602 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . 50.65 63.19 10.31 Favored Pre-proline 0 CA--C 1.531 0.232 0 N-CA-C 109.757 -0.46 . . . . 1.28 109.757 -170.679 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.405 ' HB3' ' HBA' ' A' ' 11' ' ' HZP . 31.3 Cg_exo -59.65 140.68 94.79 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 123.237 2.625 . . . . 2.4199999999999999 113.26 -170.953 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -144.91 -53.41 0.03 OUTLIER Glycine 0 N--CA 1.448 -0.558 0 C-N-CA 120.766 -0.73 . . . . 1.73 112.473 178.866 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 60.1 m80 -97.02 -105.56 0.17 Allowed 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.653 0.263 . . . . 4.2999999999999998 111.349 -178.495 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.607 ' N ' ' HD ' ' A' ' 11' ' ' HZP . 47.0 t -66.57 -45.53 78.99 Favored 'General case' 0 CA--C 1.538 0.486 0 CA-C-O 119.269 -0.396 . . . . 3.75 111.821 -179.509 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' HZP . . . . . 0.607 ' HD ' ' N ' ' A' ' 10' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 162.37 145.54 4.37 Favored Glycine 0 N--CA 1.444 -0.827 0 C-N-CA 120.855 -0.688 . . . . 2.0600000000000001 112.433 177.246 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 8.0 p -99.47 -28.43 3.44 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-O 121.387 0.613 . . . . 4.25 109.539 174.829 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -135.66 0.72 3.46 Favored Glycine 0 N--CA 1.448 -0.508 0 CA-C-N 115.498 -0.774 . . . . 3.8199999999999998 111.789 176.888 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 82.9 t60 . . . . . 0 C--O 1.245 0.832 0 CA-C-O 118.439 -0.791 . . . . 5.3099999999999996 109.874 179.712 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' PHE . . . . . 0.497 ' HB3' ' OG1' ' A' ' 5' ' ' THR . 98.8 m-85 . . . . . 0 N--CA 1.454 -0.266 0 CA-C-O 121.223 0.535 . . . . 3.26 109.928 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 51.4 mtm180 . . . . . 0 C--N 1.323 -0.558 0 CA-C-N 115.417 -0.81 . . . . 4.74 112.574 -175.434 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . 0.497 ' OG1' ' HB3' ' A' ' 2' ' ' PHE . 14.6 m . . . . . 0 N--CA 1.449 -0.479 0 N-CA-C 109.777 -0.453 . . . . 1.87 109.777 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . 56.36 69.26 1.86 Allowed Pre-proline 0 C--N 1.331 -0.21 0 CA-C-N 115.391 -0.822 . . . . 1.28 109.608 -171.592 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 14.6 Cg_endo -55.99 93.85 0.05 OUTLIER 'Trans proline' 0 C--N 1.348 0.53 0 C-N-CA 123.325 2.683 . . . . 2.42 113.339 -173.261 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -98.59 -139.97 11.15 Favored Glycine 0 N--CA 1.446 -0.651 0 C-N-CA 120.769 -0.729 . . . . 1.73 112.74 179.081 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' HIS . . . . . 0.586 ' O ' ' HA ' ' A' ' 13' ' ' VAL . 74.9 t60 -70.25 -43.35 70.71 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 111.594 0.22 . . . . 4.3 111.594 -173.695 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 18.0 m . . . . . 0 C--N 1.322 -0.595 0 N-CA-C 112.027 0.381 . . . . 3.75 112.027 179.618 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.339 0 N-CA-C 112.652 -0.179 . . . . 2.06 112.652 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.586 ' HA ' ' O ' ' A' ' 9' ' ' HIS . 7.2 t 57.8 43.12 0.3 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.355 0 CA-C-O 121.778 0.799 . . . . 4.25 109.982 -177.004 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 81.1 14.15 79.72 Favored Glycine 0 N--CA 1.449 -0.449 0 CA-C-N 115.6 -0.727 . . . . 3.82 112.626 -179.934 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 47.1 t-80 . . . . . 0 C--O 1.247 0.961 0 CA-C-O 118.736 -0.649 . . . . 5.31 110.106 178.38 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 80.9 m-85 . . . . . 0 C--O 1.231 0.082 0 CA-C-O 120.648 0.261 . . . . 3.26 110.602 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 65.2 mtm180 . . . . . 0 C--N 1.319 -0.748 0 CA-C-N 116.306 -0.407 . . . . 4.74 111.672 179.304 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 50.6 m . . . . . 0 N--CA 1.457 -0.12 0 N-CA-C 110.515 -0.18 . . . . 1.87 110.515 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . 50.42 63.28 10.24 Favored Pre-proline 0 N--CA 1.463 0.216 0 O-C-N 123.796 0.685 . . . . 1.28 109.841 -173.855 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.439 ' HB2' ' HA ' ' A' ' 15' ' ' HIS . 11.0 Cg_exo -68.68 107.24 1.61 Allowed 'Trans proline' 0 N--CA 1.46 -0.499 0 C-N-CA 122.753 2.302 . . . . 2.42 113.291 -168.718 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -101.47 -142.42 12.69 Favored Glycine 0 N--CA 1.445 -0.709 0 CA-C-N 115.685 -0.689 . . . . 1.73 112.135 175.833 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' HIS . . . . . 0.409 ' O ' ' HA ' ' A' ' 13' ' ' VAL . 33.3 m80 -66.79 -40.05 88.0 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 111.883 0.327 . . . . 4.3 111.883 -176.145 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 51.9 m . . . . . 0 CA--C 1.54 0.564 0 N-CA-C 112.03 0.382 . . . . 3.75 112.03 -178.645 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.362 0 CA-C-O 120.152 -0.249 . . . . 2.06 112.972 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.409 ' HA ' ' O ' ' A' ' 9' ' ' HIS . 7.7 t 55.34 42.02 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.462 0.162 0 CA-C-O 122.121 0.963 . . . . 4.25 108.903 -175.682 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.472 ' O ' ' HB2' ' A' ' 15' ' ' HIS . . . 128.49 -52.31 0.83 Allowed Glycine 0 N--CA 1.442 -0.91 0 CA-C-N 114.861 -1.063 . . . . 3.82 110.869 -174.387 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' HIS . . . . . 0.472 ' HB2' ' O ' ' A' ' 14' ' ' GLY . 38.7 t-80 . . . . . 0 C--O 1.245 0.84 0 C-N-CA 123.513 0.725 . . . . 5.31 109.478 178.932 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' PHE . . . . . 0.475 ' HB3' ' HB ' ' A' ' 5' ' ' THR . 94.3 m-85 . . . . . 0 N--CA 1.464 0.235 0 CA-C-O 120.973 0.416 . . . . 3.26 110.9 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 41.0 mtp180 . . . . . 0 C--N 1.325 -0.457 0 CA-C-N 115.762 -0.653 . . . . 4.74 112.428 -176.763 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . 0.475 ' HB ' ' HB3' ' A' ' 2' ' ' PHE . 8.4 m . . . . . 0 N--CA 1.454 -0.236 0 N-CA-C 110.346 -0.242 . . . . 1.87 110.346 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . 51.0 64.09 8.75 Favored Pre-proline 0 C--O 1.234 0.26 0 N-CA-C 109.554 -0.536 . . . . 1.28 109.554 -173.627 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -57.64 97.62 0.08 OUTLIER 'Trans proline' 0 C--N 1.345 0.375 0 C-N-CA 123.597 2.865 . . . . 2.42 113.738 -167.525 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -95.72 -150.09 26.55 Favored Glycine 0 N--CA 1.445 -0.704 0 CA-C-N 115.566 -0.743 . . . . 1.73 111.765 174.952 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 86.1 t60 -73.25 -43.31 61.35 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 120.598 0.237 . . . . 4.3 111.452 -176.083 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 48.4 m . . . . . 0 C--N 1.323 -0.565 0 N-CA-C 111.949 0.352 . . . . 3.75 111.949 -179.297 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.823 0 N-CA-C 112.369 -0.292 . . . . 2.06 112.369 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 40.3 t -59.63 -32.6 49.57 Favored 'Isoleucine or valine' 0 C--O 1.234 0.258 0 CA-C-O 121.329 0.585 . . . . 4.25 110.07 178.029 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -112.58 23.88 14.53 Favored Glycine 0 N--CA 1.447 -0.577 0 N-CA-C 111.062 -0.815 . . . . 3.82 111.062 173.467 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 6.8 t60 . . . . . 0 C--O 1.248 0.99 0 CA-C-O 118.287 -0.864 . . . . 5.31 110.16 -178.505 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 29.6 p90 . . . . . 0 N--CA 1.458 -0.039 0 CA-C-O 121.387 0.613 . . . . 3.26 110.661 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 18.2 mtp180 . . . . . 0 C--N 1.322 -0.617 0 CA-C-N 115.934 -0.575 . . . . 4.74 112.32 -178.969 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 40.9 p . . . . . 0 N--CA 1.454 -0.229 0 CA-C-O 120.905 0.383 . . . . 1.87 110.177 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . 57.72 68.81 1.78 Allowed Pre-proline 0 N--CA 1.462 0.128 0 CA-C-N 115.475 -0.784 . . . . 1.28 109.806 -172.533 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_exo -56.25 99.73 0.08 OUTLIER 'Trans proline' 0 C--N 1.347 0.486 0 C-N-CA 123.616 2.877 . . . . 2.42 113.756 -169.92 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -104.07 -130.77 6.97 Favored Glycine 0 N--CA 1.442 -0.906 0 CA-C-N 115.634 -0.712 . . . . 1.73 111.73 174.658 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 39.7 m80 -86.26 -59.14 2.37 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.882 0.372 . . . . 4.3 110.719 -176.465 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 55.9 m . . . . . 0 CA--C 1.539 0.535 0 N-CA-C 112.572 0.582 . . . . 3.75 112.572 -178.588 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.457 ' HA3' ' O ' ' A' ' 15' ' ' HIS . . . . . . . . 0 C--O 1.23 -0.123 0 CA-C-O 120.007 -0.329 . . . . 2.06 113.667 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 6.3 t 53.24 42.62 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.331 0 CA-C-O 121.83 0.824 . . . . 4.25 109.622 -175.778 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 112.12 -29.66 8.24 Favored Glycine 0 N--CA 1.447 -0.602 0 CA-C-N 115.59 -0.732 . . . . 3.82 112.456 -177.213 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' HIS . . . . . 0.457 ' O ' ' HA3' ' A' ' 12' ' ' GLY . 83.3 t60 . . . . . 0 C--O 1.246 0.891 0 CA-C-O 118.905 -0.569 . . . . 5.31 109.95 -178.58 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 92.1 m-85 . . . . . 0 C--O 1.232 0.176 0 CA-C-O 121.198 0.523 . . . . 3.26 110.103 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 65.1 mtp180 . . . . . 0 C--N 1.322 -0.598 0 N-CA-C 112.933 0.716 . . . . 4.74 112.933 -175.875 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 22.7 p . . . . . 0 C--O 1.234 0.257 0 N-CA-C 110.79 -0.078 . . . . 1.87 110.79 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . 55.98 74.57 0.68 Allowed Pre-proline 0 C--O 1.232 0.172 0 O-C-N 123.811 0.694 . . . . 1.28 110.646 -177.013 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_exo -51.56 94.38 0.03 OUTLIER 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 124.12 3.214 . . . . 2.42 114.144 -174.836 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -89.76 -164.97 40.46 Favored Glycine 0 N--CA 1.445 -0.714 0 N-CA-C 111.432 -0.667 . . . . 1.73 111.432 172.456 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' HIS . . . . . 0.598 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 55.5 t-80 -67.82 -25.43 65.56 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.798 0.333 . . . . 4.3 111.049 -178.255 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 45.3 t . . . . . 0 CA--C 1.54 0.571 0 CA-C-O 119.374 -0.346 . . . . 3.75 111.383 177.429 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.445 -0.762 0 N-CA-C 112.36 -0.296 . . . . 2.06 112.36 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.598 ' HB ' ' O ' ' A' ' 9' ' ' HIS . 7.3 p -60.57 -36.74 72.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-O 120.865 0.364 . . . . 4.25 110.858 177.575 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -115.09 -23.06 4.7 Favored Glycine 0 N--CA 1.446 -0.666 0 C-N-CA 120.771 -0.728 . . . . 3.82 112.308 179.652 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 54.8 t-80 . . . . . 0 C--O 1.248 1.007 0 CA-C-O 118.48 -0.771 . . . . 5.31 110.107 -179.664 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 66.3 m-85 . . . . . 0 N--CA 1.454 -0.249 0 N-CA-C 109.821 -0.437 . . . . 3.26 109.821 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 . . . . . 0 C--N 1.322 -0.592 0 CA-C-O 118.986 -0.531 . . . . 4.74 112.171 -176.296 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 96.8 m . . . . . 0 N--CA 1.454 -0.253 0 N-CA-C 108.814 -0.81 . . . . 1.87 108.814 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . 57.25 73.69 0.75 Allowed Pre-proline 0 C--O 1.233 0.232 0 CA-C-O 121.252 0.549 . . . . 1.28 109.69 -174.093 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 25.0 Cg_exo -63.2 137.49 61.51 Favored 'Trans proline' 0 C--O 1.235 0.329 0 C-N-CA 123.426 2.75 . . . . 2.42 113.395 -170.734 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -147.02 -70.69 0.01 OUTLIER Glycine 0 N--CA 1.446 -0.687 0 C-N-CA 120.889 -0.672 . . . . 1.73 112.739 177.807 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 85.4 t60 -87.53 -81.59 0.24 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.862 0.331 . . . . 4.3 111.723 -174.737 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 5.3 p . . . . . 0 CA--C 1.54 0.575 0 N-CA-C 113.233 0.827 . . . . 3.75 113.233 -174.964 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.441 -0.973 0 N-CA-C 110.764 -0.934 . . . . 2.06 110.764 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 7.7 p -88.34 -30.28 5.45 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 N-CA-C 109.419 -0.585 . . . . 4.25 109.419 173.822 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -148.46 14.61 1.24 Allowed Glycine 0 N--CA 1.448 -0.536 0 CA-C-N 115.606 -0.725 . . . . 3.82 111.78 176.792 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 58.5 t-80 . . . . . 0 C--O 1.249 1.028 0 CA-C-O 118.453 -0.784 . . . . 5.31 110.445 -178.15 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 99.0 m-85 . . . . . 0 N--CA 1.463 0.176 0 CA-C-O 121.214 0.53 . . . . 3.26 110.393 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 73.7 mtm180 . . . . . 0 C--N 1.322 -0.591 0 N-CA-C 113.393 0.886 . . . . 4.74 113.393 -176.023 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 9.2 m . . . . . 0 N--CA 1.452 -0.347 0 CA-C-O 120.471 0.177 . . . . 1.87 111.065 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . 57.75 73.62 0.74 Allowed Pre-proline 0 N--CA 1.466 0.35 0 CA-C-N 115.991 -0.55 . . . . 1.28 112.106 179.042 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.618 ' HB3' ' H ' ' A' ' 13' ' ' VAL . 6.0 Cg_endo -49.04 143.92 17.03 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 123.622 2.882 . . . . 2.42 113.558 179.472 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 179.22 -112.88 0.38 Allowed Glycine 0 N--CA 1.446 -0.691 0 C-N-CA 120.74 -0.743 . . . . 1.73 112.671 176.982 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 16.4 t60 -82.01 -70.87 0.51 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.571 0.185 . . . . 4.3 110.881 -177.581 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 19.1 t . . . . . 0 CA--C 1.537 0.461 0 C-N-CA 120.756 -0.378 . . . . 3.75 110.247 176.9 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.698 0 N-CA-C 112.802 -0.119 . . . . 2.06 112.802 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.618 ' H ' ' HB3' ' A' ' 7' ' ' PRO . 52.3 t -67.75 -41.23 85.06 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-O 121.068 0.461 . . . . 4.25 110.11 177.222 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -126.89 18.6 6.23 Favored Glycine 0 N--CA 1.448 -0.517 0 C-N-CA 121.04 -0.6 . . . . 3.82 111.622 175.963 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 9.4 t60 . . . . . 0 C--O 1.243 0.753 0 CA-C-O 118.44 -0.79 . . . . 5.31 109.891 -176.775 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 84.4 m-85 . . . . . 0 N--CA 1.464 0.273 0 CA-C-O 121.184 0.516 . . . . 3.26 110.831 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' ARG . . . . . 0.643 ' O ' ' HG3' ' A' ' 7' ' ' PRO . 99.5 mtt180 . . . . . 0 CA--C 1.539 0.546 0 CA-C-N 115.726 -0.67 . . . . 4.74 112.552 -176.8 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 3.9 t . . . . . 0 N--CA 1.453 -0.278 0 CA-C-O 121.42 0.629 . . . . 1.87 111.803 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . 52.29 73.59 0.93 Allowed Pre-proline 0 C--N 1.33 -0.256 0 CA-C-N 115.07 -0.968 . . . . 1.28 112.507 177.752 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.643 ' HG3' ' O ' ' A' ' 3' ' ' ARG . 5.9 Cg_endo -84.6 -53.65 0.03 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.616 0 C-N-CA 123.17 2.58 . . . . 2.42 111.069 177.367 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -143.96 68.58 0.42 Allowed Glycine 0 N--CA 1.443 -0.858 0 N-CA-C 109.985 -1.246 . . . . 1.73 109.985 174.916 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 99.5 m-70 71.67 -61.7 0.48 Allowed 'General case' 0 N--CA 1.468 0.454 0 C-N-CA 123.571 0.748 . . . . 4.3 110.805 -173.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 26.1 m . . . . . 0 C--N 1.325 -0.492 0 CA-C-N 116.677 -0.238 . . . . 3.75 110.8 179.636 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.471 0 N-CA-C 112.159 -0.376 . . . . 2.06 112.159 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 6.3 m -67.95 83.1 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-O 121.666 0.746 . . . . 4.25 110.049 172.747 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 130.99 -15.93 5.33 Favored Glycine 0 N--CA 1.445 -0.76 0 CA-C-N 115.39 -0.823 . . . . 3.82 111.354 -174.003 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 73.3 t60 . . . . . 0 C--O 1.245 0.817 0 CA-C-O 118.758 -0.639 . . . . 5.31 109.579 178.091 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 76.5 m-85 . . . . . 0 N--CA 1.454 -0.268 0 CA-C-O 120.942 0.401 . . . . 3.26 110.512 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 84.1 mtt180 . . . . . 0 C--N 1.321 -0.665 0 CA-C-O 119.086 -0.483 . . . . 4.74 111.684 176.631 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 10.9 p . . . . . 0 C--O 1.235 0.293 0 N-CA-C 109.741 -0.466 . . . . 1.87 109.741 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . 66.23 94.91 0.05 OUTLIER Pre-proline 0 C--N 1.333 -0.137 0 CA-C-N 115.52 -0.764 . . . . 1.28 110.754 -177.725 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_exo -64.88 102.92 0.44 Allowed 'Trans proline' 0 C--O 1.232 0.222 0 C-N-CA 122.702 2.268 . . . . 2.42 112.31 -179.417 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -160.98 51.52 0.34 Allowed Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 120.901 -0.666 . . . . 1.73 112.223 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 40.4 t-80 -174.23 -47.35 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.23 0.538 . . . . 4.3 109.73 -179.421 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 23.3 t . . . . . 0 C--N 1.323 -0.564 0 CA-C-N 115.345 -0.843 . . . . 3.75 110.259 -177.147 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.808 0 N-CA-C 112.255 -0.338 . . . . 2.06 112.255 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 73.4 t -62.2 -52.95 54.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 N-CA-C 109.414 -0.587 . . . . 4.25 109.414 178.478 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -107.04 23.41 27.51 Favored Glycine 0 N--CA 1.443 -0.863 0 N-CA-C 110.782 -0.927 . . . . 3.82 110.782 172.773 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 41.9 m80 . . . . . 0 C--O 1.25 1.089 0 CA-C-N 115.089 -0.556 . . . . 5.31 110.403 -176.476 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 75.5 m-85 . . . . . 0 N--CA 1.453 -0.283 0 CA-C-O 121.19 0.519 . . . . 3.26 109.726 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' ARG . . . . . 0.402 HH11 ' HD3' ' A' ' 3' ' ' ARG . 47.6 mtm-85 . . . . . 0 C--N 1.325 -0.488 0 CA-C-N 115.842 -0.617 . . . . 4.74 111.964 -176.162 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 8.9 t . . . . . 0 N--CA 1.449 -0.51 0 N-CA-C 108.442 -0.947 . . . . 1.87 108.442 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . 50.65 63.19 10.31 Favored Pre-proline 0 CA--C 1.531 0.232 0 N-CA-C 109.757 -0.46 . . . . 1.28 109.757 -170.679 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -59.65 140.68 94.79 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 123.237 2.625 . . . . 2.42 113.26 -170.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -144.91 -53.41 0.03 OUTLIER Glycine 0 N--CA 1.448 -0.558 0 C-N-CA 120.766 -0.73 . . . . 1.73 112.473 178.866 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 60.1 m80 -97.02 -105.56 0.17 Allowed 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.653 0.263 . . . . 4.3 111.349 -178.495 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 47.0 t . . . . . 0 CA--C 1.538 0.486 0 CA-C-O 119.269 -0.396 . . . . 3.75 111.821 -179.509 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.827 0 N-CA-C 112.433 -0.267 . . . . 2.06 112.433 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 8.0 p -99.47 -28.43 3.44 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-O 121.387 0.613 . . . . 4.25 109.539 174.829 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -135.66 0.72 3.46 Favored Glycine 0 N--CA 1.448 -0.508 0 CA-C-N 115.498 -0.774 . . . . 3.82 111.789 176.888 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 82.9 t60 . . . . . 0 C--O 1.245 0.832 0 CA-C-O 118.439 -0.791 . . . . 5.31 109.874 179.712 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 0.983 0 CA-C-O 120.696 0.284 . . . . 4.02 110.357 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . 0.497 ' HB3' ' OG1' ' A' ' 5' ' ' THR . 98.8 m-85 -99.38 88.98 4.03 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 121.223 0.535 . . . . 3.26 109.928 179.259 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . 0.465 ' HB2' ' HDA' ' A' ' 4' ' ' HZP . 51.4 mtm180 -68.32 -52.22 35.93 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.417 -0.81 . . . . 4.74 112.574 -175.434 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' HZP . . . . . 0.465 ' HDA' ' HB2' ' A' ' 3' ' ' ARG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.497 ' OG1' ' HB3' ' A' ' 2' ' ' PHE . 14.6 m -98.62 90.87 4.88 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 109.777 -0.453 . . . . 1.87 109.777 -175.667 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . 56.36 69.26 1.86 Allowed Pre-proline 0 C--N 1.331 -0.21 0 CA-C-N 115.391 -0.822 . . . . 1.28 109.608 -171.592 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.526 ' HA ' ' HBA' ' A' ' 11' ' ' HZP . 14.6 Cg_endo -55.99 93.85 0.05 OUTLIER 'Trans proline' 0 C--N 1.348 0.53 0 C-N-CA 123.325 2.683 . . . . 2.42 113.339 -173.261 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -98.59 -139.97 11.15 Favored Glycine 0 N--CA 1.446 -0.651 0 C-N-CA 120.769 -0.729 . . . . 1.73 112.74 179.081 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . 0.586 ' O ' ' HA ' ' A' ' 13' ' ' VAL . 74.9 t60 -70.25 -43.35 70.71 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 111.594 0.22 . . . . 4.3 111.594 -173.695 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.495 ' HB2' ' HDA' ' A' ' 11' ' ' HZP . 18.0 m -93.62 -49.63 5.78 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 112.027 0.381 . . . . 3.75 112.027 179.618 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' HZP . . . . . 0.526 ' HBA' ' HA ' ' A' ' 7' ' ' PRO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -96.74 -5.56 58.64 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.587 -0.816 . . . . 2.06 112.652 -176.852 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.586 ' HA ' ' O ' ' A' ' 9' ' ' HIS . 7.2 t 57.8 43.12 0.3 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.355 0 CA-C-O 121.778 0.799 . . . . 4.25 109.982 -177.004 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 81.1 14.15 79.72 Favored Glycine 0 N--CA 1.449 -0.449 0 CA-C-N 115.6 -0.727 . . . . 3.82 112.626 -179.934 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 47.1 t-80 . . . . . 0 C--O 1.247 0.961 0 CA-C-O 118.736 -0.649 . . . . 5.31 110.106 178.38 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.069 0 CA-C-O 120.609 0.243 . . . . 4.02 110.928 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 80.9 m-85 -83.76 160.92 21.15 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.648 0.261 . . . . 3.26 110.602 -179.352 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . 0.514 ' HB2' ' HDA' ' A' ' 4' ' ' HZP . 65.2 mtm180 -72.87 -53.1 12.28 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 116.306 -0.407 . . . . 4.74 111.672 179.304 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' HZP . . . . . 0.514 ' HDA' ' HB2' ' A' ' 3' ' ' ARG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 50.6 m -127.06 107.82 10.38 Favored 'General case' 0 C--N 1.326 -0.442 0 C-N-CA 120.967 -0.293 . . . . 1.87 110.515 -177.906 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . 50.42 63.28 10.24 Favored Pre-proline 0 N--CA 1.463 0.216 0 O-C-N 123.796 0.685 . . . . 1.28 109.841 -173.855 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.57 ' HA ' ' HBA' ' A' ' 11' ' ' HZP . 11.0 Cg_exo -68.68 107.24 1.61 Allowed 'Trans proline' 0 N--CA 1.46 -0.499 0 C-N-CA 122.753 2.302 . . . . 2.42 113.291 -168.718 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -101.47 -142.42 12.69 Favored Glycine 0 N--CA 1.445 -0.709 0 CA-C-N 115.685 -0.689 . . . . 1.73 112.135 175.833 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . 0.409 ' O ' ' HA ' ' A' ' 13' ' ' VAL . 33.3 m80 -66.79 -40.05 88.0 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 111.883 0.327 . . . . 4.3 111.883 -176.145 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.561 ' HB2' ' HDA' ' A' ' 11' ' ' HZP . 51.9 m -85.72 -55.44 3.98 Favored 'General case' 0 CA--C 1.54 0.564 0 N-CA-C 112.03 0.382 . . . . 3.75 112.03 -178.645 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' HZP . . . . . 0.57 ' HBA' ' HA ' ' A' ' 7' ' ' PRO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -91.91 6.16 79.25 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.784 -0.722 . . . . 2.06 112.972 -177.144 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.409 ' HA ' ' O ' ' A' ' 9' ' ' HIS . 7.7 t 55.34 42.02 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.462 0.162 0 CA-C-O 122.121 0.963 . . . . 4.25 108.903 -175.682 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.472 ' O ' ' HB2' ' A' ' 15' ' ' HIS . . . 128.49 -52.31 0.83 Allowed Glycine 0 N--CA 1.442 -0.91 0 CA-C-N 114.861 -1.063 . . . . 3.82 110.869 -174.387 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' HIS . . . . . 0.472 ' HB2' ' O ' ' A' ' 14' ' ' GLY . 38.7 t-80 . . . . . 0 C--O 1.245 0.84 0 C-N-CA 123.513 0.725 . . . . 5.31 109.478 178.932 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.012 0 N-CA-C 110.221 -0.288 . . . . 4.02 110.221 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . 0.475 ' HB3' ' HB ' ' A' ' 5' ' ' THR . 94.3 m-85 60.11 65.17 1.13 Allowed 'General case' 0 N--CA 1.464 0.235 0 O-C-N 123.476 0.485 . . . . 3.26 110.9 179.566 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . 0.423 ' HB2' ' HDA' ' A' ' 4' ' ' HZP . 41.0 mtp180 -70.4 -50.35 39.49 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.762 -0.653 . . . . 4.74 112.428 -176.763 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' HZP . . . . . 0.423 ' HDA' ' HB2' ' A' ' 3' ' ' ARG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.475 ' HB ' ' HB3' ' A' ' 2' ' ' PHE . 8.4 m -94.85 102.02 13.85 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.617 -0.265 . . . . 1.87 110.346 -173.903 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . 51.0 64.09 8.75 Favored Pre-proline 0 C--O 1.234 0.26 0 N-CA-C 109.554 -0.536 . . . . 1.28 109.554 -173.627 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -57.64 97.62 0.08 OUTLIER 'Trans proline' 0 C--N 1.345 0.375 0 C-N-CA 123.597 2.865 . . . . 2.42 113.738 -167.525 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -95.72 -150.09 26.55 Favored Glycine 0 N--CA 1.445 -0.704 0 CA-C-N 115.566 -0.743 . . . . 1.73 111.765 174.952 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 86.1 t60 -73.25 -43.31 61.35 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 120.598 0.237 . . . . 4.3 111.452 -176.083 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.524 ' HB2' ' HDA' ' A' ' 11' ' ' HZP . 48.4 m -78.94 -48.3 14.79 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 111.949 0.352 . . . . 3.75 111.949 -179.297 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' HZP . . . . . 0.524 ' HDA' ' HB2' ' A' ' 10' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 140.93 103.39 0.52 Allowed Glycine 0 N--CA 1.444 -0.823 0 C-N-CA 120.951 -0.642 . . . . 2.06 112.369 175.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 40.3 t -59.63 -32.6 49.57 Favored 'Isoleucine or valine' 0 C--O 1.234 0.258 0 CA-C-O 121.329 0.585 . . . . 4.25 110.07 178.029 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -112.58 23.88 14.53 Favored Glycine 0 N--CA 1.447 -0.577 0 N-CA-C 111.062 -0.815 . . . . 3.82 111.062 173.467 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 6.8 t60 . . . . . 0 C--O 1.248 0.99 0 CA-C-O 118.287 -0.864 . . . . 5.31 110.16 -178.505 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.949 0 CA-C-O 120.551 0.215 . . . . 4.02 110.752 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . 0.564 ' O ' ' HB ' ' A' ' 11' ' ' HZP . 29.6 p90 -137.07 38.41 2.55 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.387 0.613 . . . . 3.26 110.661 -179.059 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . 0.524 ' HG2' ' O ' ' A' ' 11' ' ' HZP . 18.2 mtp180 -64.62 -50.5 66.91 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.934 -0.575 . . . . 4.74 112.32 -178.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' HZP . . . . . 0.472 ' HA ' ' HG3' ' A' ' 7' ' ' PRO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 40.9 p -90.36 82.52 5.94 Favored 'General case' 0 C--N 1.326 -0.429 0 C-N-CA 120.437 -0.505 . . . . 1.87 110.177 -179.778 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . 57.72 68.81 1.78 Allowed Pre-proline 0 N--CA 1.462 0.128 0 CA-C-N 115.475 -0.784 . . . . 1.28 109.806 -172.533 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.472 ' HG3' ' HA ' ' A' ' 4' ' ' HZP . 37.0 Cg_exo -56.25 99.73 0.08 OUTLIER 'Trans proline' 0 C--N 1.347 0.486 0 C-N-CA 123.616 2.877 . . . . 2.42 113.756 -169.92 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -104.07 -130.77 6.97 Favored Glycine 0 N--CA 1.442 -0.906 0 CA-C-N 115.634 -0.712 . . . . 1.73 111.73 174.658 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 39.7 m80 -86.26 -59.14 2.37 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.882 0.372 . . . . 4.3 110.719 -176.465 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.497 ' HB2' ' HDA' ' A' ' 11' ' ' HZP . 55.9 m -62.4 -48.75 78.34 Favored 'General case' 0 CA--C 1.539 0.535 0 N-CA-C 112.572 0.582 . . . . 3.75 112.572 -178.588 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' HZP . . . . . 0.564 ' HB ' ' O ' ' A' ' 2' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.457 ' HA3' ' O ' ' A' ' 15' ' ' HIS . . . -132.9 15.99 4.79 Favored Glycine 0 C--N 1.329 0.149 0 C-N-CA 119.705 -1.235 . . . . 2.06 113.667 -176.201 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 6.3 t 53.24 42.62 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.331 0 CA-C-O 121.83 0.824 . . . . 4.25 109.622 -175.778 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 112.12 -29.66 8.24 Favored Glycine 0 N--CA 1.447 -0.602 0 CA-C-N 115.59 -0.732 . . . . 3.82 112.456 -177.213 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' HIS . . . . . 0.457 ' O ' ' HA3' ' A' ' 12' ' ' GLY . 83.3 t60 . . . . . 0 C--O 1.246 0.891 0 CA-C-O 118.905 -0.569 . . . . 5.31 109.95 -178.58 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.936 0 N-CA-C 110.28 -0.267 . . . . 4.02 110.28 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 92.1 m-85 -72.33 122.19 20.73 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 121.198 0.523 . . . . 3.26 110.103 178.166 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . 0.46 ' N ' ' HD ' ' A' ' 4' ' ' HZP . 65.1 mtp180 -80.04 -47.82 14.28 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 112.933 0.716 . . . . 4.74 112.933 -175.875 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' HZP . . . . . 0.46 ' HD ' ' N ' ' A' ' 3' ' ' ARG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 22.7 p -114.26 110.94 20.72 Favored 'General case' 0 C--N 1.323 -0.552 0 O-C-N 122.364 -0.21 . . . . 1.87 110.79 -177.778 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . 55.98 74.57 0.68 Allowed Pre-proline 0 C--O 1.232 0.172 0 O-C-N 123.811 0.694 . . . . 1.28 110.646 -177.013 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_exo -51.56 94.38 0.03 OUTLIER 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 124.12 3.214 . . . . 2.42 114.144 -174.836 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -89.76 -164.97 40.46 Favored Glycine 0 N--CA 1.445 -0.714 0 N-CA-C 111.432 -0.667 . . . . 1.73 111.432 172.456 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . 0.598 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 55.5 t-80 -67.82 -25.43 65.56 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.798 0.333 . . . . 4.3 111.049 -178.255 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.559 ' HB3' ' HDA' ' A' ' 11' ' ' HZP . 45.3 t -101.9 -53.14 3.01 Favored 'General case' 0 CA--C 1.54 0.571 0 CA-C-O 119.374 -0.346 . . . . 3.75 111.383 177.429 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' HZP . . . . . 0.559 ' HDA' ' HB3' ' A' ' 10' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -140.68 58.99 0.57 Allowed Glycine 0 N--CA 1.445 -0.762 0 C-N-CA 120.491 -0.861 . . . . 2.06 112.36 -175.257 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.598 ' HB ' ' O ' ' A' ' 9' ' ' HIS . 7.3 p -60.57 -36.74 72.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-O 120.865 0.364 . . . . 4.25 110.858 177.575 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -115.09 -23.06 4.7 Favored Glycine 0 N--CA 1.446 -0.666 0 C-N-CA 120.771 -0.728 . . . . 3.82 112.308 179.652 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 54.8 t-80 . . . . . 0 C--O 1.248 1.007 0 CA-C-O 118.48 -0.771 . . . . 5.31 110.107 -179.664 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.039 0 CA-C-O 120.605 0.241 . . . . 4.02 110.648 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 66.3 m-85 -89.86 174.64 7.58 Favored 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 109.821 -0.437 . . . . 3.26 109.821 174.415 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . 0.617 ' O ' ' HG ' ' A' ' 11' ' ' HZP . 99.8 mtt180 -68.11 -63.39 1.07 Allowed 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 118.986 -0.531 . . . . 4.74 112.171 -176.296 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' HZP . . . . . 0.467 ' HDA' ' HB2' ' A' ' 3' ' ' ARG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 96.8 m -162.12 125.28 3.01 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 108.814 -0.81 . . . . 1.87 108.814 -177.755 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . 57.25 73.69 0.75 Allowed Pre-proline 0 C--O 1.233 0.232 0 CA-C-O 121.252 0.549 . . . . 1.28 109.69 -174.093 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 25.0 Cg_exo -63.2 137.49 61.51 Favored 'Trans proline' 0 C--O 1.235 0.329 0 C-N-CA 123.426 2.75 . . . . 2.42 113.395 -170.734 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -147.02 -70.69 0.01 OUTLIER Glycine 0 N--CA 1.446 -0.687 0 C-N-CA 120.889 -0.672 . . . . 1.73 112.739 177.807 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 85.4 t60 -87.53 -81.59 0.24 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.862 0.331 . . . . 4.3 111.723 -174.737 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.607 ' N ' ' HD ' ' A' ' 11' ' ' HZP . 5.3 p -90.3 -42.32 11.04 Favored 'General case' 0 CA--C 1.54 0.575 0 N-CA-C 113.233 0.827 . . . . 3.75 113.233 -174.964 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' HZP . . . . . 0.617 ' HG ' ' O ' ' A' ' 3' ' ' ARG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 160.38 -177.13 36.94 Favored Glycine 0 N--CA 1.441 -0.973 0 CA-C-N 114.528 -1.215 . . . . 2.06 110.764 176.356 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 7.7 p -88.34 -30.28 5.45 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 N-CA-C 109.419 -0.585 . . . . 4.25 109.419 173.822 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -148.46 14.61 1.24 Allowed Glycine 0 N--CA 1.448 -0.536 0 CA-C-N 115.606 -0.725 . . . . 3.82 111.78 176.792 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 58.5 t-80 . . . . . 0 C--O 1.249 1.028 0 CA-C-O 118.453 -0.784 . . . . 5.31 110.445 -178.15 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.115 0 N-CA-C 110.451 -0.203 . . . . 4.02 110.451 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 99.0 m-85 55.84 65.25 1.5 Allowed 'General case' 0 N--CA 1.463 0.176 0 CA-C-O 121.214 0.53 . . . . 3.26 110.393 -179.441 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . 0.526 ' N ' ' HD ' ' A' ' 4' ' ' HZP . 73.7 mtm180 -64.62 -44.09 91.68 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 113.393 0.886 . . . . 4.74 113.393 -176.023 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' HZP . . . . . 0.526 ' HD ' ' N ' ' A' ' 3' ' ' ARG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 9.2 m -126.64 112.88 15.99 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 120.471 0.177 . . . . 1.87 111.065 -177.537 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . 57.75 73.62 0.74 Allowed Pre-proline 0 N--CA 1.466 0.35 0 CA-C-N 115.991 -0.55 . . . . 1.28 112.106 179.042 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.618 ' HB3' ' H ' ' A' ' 13' ' ' VAL . 6.0 Cg_endo -49.04 143.92 17.03 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 123.622 2.882 . . . . 2.42 113.558 179.472 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 179.22 -112.88 0.38 Allowed Glycine 0 N--CA 1.446 -0.691 0 C-N-CA 120.74 -0.743 . . . . 1.73 112.671 176.982 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 16.4 t60 -82.01 -70.87 0.51 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.571 0.185 . . . . 4.3 110.881 -177.581 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.624 ' HB3' ' HDA' ' A' ' 11' ' ' HZP . 19.1 t -71.51 -52.42 18.41 Favored 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 120.756 -0.378 . . . . 3.75 110.247 176.9 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' HZP . . . . . 0.624 ' HDA' ' HB3' ' A' ' 10' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -164.2 68.07 0.21 Allowed Glycine 0 N--CA 1.446 -0.698 0 C-N-CA 119.724 -1.227 . . . . 2.06 112.802 -175.595 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.618 ' H ' ' HB3' ' A' ' 7' ' ' PRO . 52.3 t -67.75 -41.23 85.06 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-O 121.068 0.461 . . . . 4.25 110.11 177.222 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -126.89 18.6 6.23 Favored Glycine 0 N--CA 1.448 -0.517 0 C-N-CA 121.04 -0.6 . . . . 3.82 111.622 175.963 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 9.4 t60 . . . . . 0 C--O 1.243 0.753 0 CA-C-O 118.44 -0.79 . . . . 5.31 109.891 -176.775 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.009 0 CA-C-O 120.264 0.078 . . . . 4.02 110.965 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 84.4 m-85 58.38 49.17 11.24 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-O 121.184 0.516 . . . . 3.26 110.831 -178.425 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . 0.643 ' O ' ' HG3' ' A' ' 7' ' ' PRO . 99.5 mtt180 -75.91 -45.54 34.73 Favored 'General case' 0 CA--C 1.539 0.546 0 CA-C-N 115.726 -0.67 . . . . 4.74 112.552 -176.8 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' HZP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 3.9 t -140.89 77.66 1.61 Allowed 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.42 0.629 . . . . 1.87 111.803 -174.579 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . 52.29 73.59 0.93 Allowed Pre-proline 0 C--N 1.33 -0.256 0 CA-C-N 115.07 -0.968 . . . . 1.28 112.507 177.752 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.643 ' HG3' ' O ' ' A' ' 3' ' ' ARG . 5.9 Cg_endo -84.6 -53.65 0.03 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.616 0 C-N-CA 123.17 2.58 . . . . 2.42 111.069 177.367 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -143.96 68.58 0.42 Allowed Glycine 0 N--CA 1.443 -0.858 0 N-CA-C 109.985 -1.246 . . . . 1.73 109.985 174.916 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 99.5 m-70 71.67 -61.7 0.48 Allowed 'General case' 0 N--CA 1.468 0.454 0 C-N-CA 123.571 0.748 . . . . 4.3 110.805 -173.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 26.1 m -95.7 122.56 38.59 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.677 -0.238 . . . . 3.75 110.8 179.636 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' HZP . . . . . 0.462 ' HA ' ' CD ' ' A' ' 7' ' ' PRO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -172.34 -19.33 0.02 OUTLIER Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 120.692 -0.766 . . . . 2.06 112.159 -178.012 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 6.3 m -67.95 83.1 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-O 121.666 0.746 . . . . 4.25 110.049 172.747 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 130.99 -15.93 5.33 Favored Glycine 0 N--CA 1.445 -0.76 0 CA-C-N 115.39 -0.823 . . . . 3.82 111.354 -174.003 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 73.3 t60 . . . . . 0 C--O 1.245 0.817 0 CA-C-O 118.758 -0.639 . . . . 5.31 109.579 178.091 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.97 0 CA-C-O 120.975 0.417 . . . . 4.02 110.493 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 76.5 m-85 -112.74 112.46 23.97 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.147 -0.479 . . . . 3.26 110.512 179.352 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . 0.508 ' O ' ' HB ' ' A' ' 11' ' ' HZP . 84.1 mtt180 -82.66 -50.91 8.24 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 119.086 -0.483 . . . . 4.74 111.684 176.631 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' HZP . . . . . 0.449 ' HD ' ' N ' ' A' ' 3' ' ' ARG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 10.9 p -143.85 84.83 1.8 Allowed 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 116.124 -0.489 . . . . 1.87 109.741 177.456 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . 66.23 94.91 0.05 OUTLIER Pre-proline 0 C--N 1.333 -0.137 0 CA-C-N 115.52 -0.764 . . . . 1.28 110.754 -177.725 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_exo -64.88 102.92 0.44 Allowed 'Trans proline' 0 C--O 1.232 0.222 0 C-N-CA 122.702 2.268 . . . . 2.42 112.31 -179.417 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -160.98 51.52 0.34 Allowed Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 120.901 -0.666 . . . . 1.73 112.223 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 40.4 t-80 -174.23 -47.35 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.23 0.538 . . . . 4.3 109.73 -179.421 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.644 ' N ' ' HD ' ' A' ' 11' ' ' HZP . 23.3 t -167.04 -47.83 0.02 OUTLIER 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.345 -0.843 . . . . 3.75 110.259 -177.147 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' HZP . . . . . 0.644 ' HD ' ' N ' ' A' ' 10' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -146.83 46.09 0.75 Allowed Glycine 0 N--CA 1.444 -0.808 0 C-N-CA 120.542 -0.837 . . . . 2.06 112.255 -177.573 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 73.4 t -62.2 -52.95 54.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 N-CA-C 109.414 -0.587 . . . . 4.25 109.414 178.478 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -107.04 23.41 27.51 Favored Glycine 0 N--CA 1.443 -0.863 0 N-CA-C 110.782 -0.927 . . . . 3.82 110.782 172.773 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 41.9 m80 . . . . . 0 C--O 1.25 1.089 0 CA-C-N 115.089 -0.556 . . . . 5.31 110.403 -176.476 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.968 0 CA-C-O 121.011 0.434 . . . . 4.02 110.758 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 75.5 m-85 -133.44 65.48 1.58 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.19 0.519 . . . . 3.26 109.726 176.584 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . 0.519 ' HB2' ' HDA' ' A' ' 4' ' ' HZP . 47.6 mtm-85 -87.97 -57.51 2.91 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.842 -0.617 . . . . 4.74 111.964 -176.162 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' HZP . . . . . 0.519 ' HDA' ' HB2' ' A' ' 3' ' ' ARG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 8.9 t -158.86 132.52 7.48 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 108.442 -0.947 . . . . 1.87 108.442 177.602 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . 50.65 63.19 10.31 Favored Pre-proline 0 CA--C 1.531 0.232 0 N-CA-C 109.757 -0.46 . . . . 1.28 109.757 -170.679 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.405 ' HB3' ' HBA' ' A' ' 11' ' ' HZP . 31.3 Cg_exo -59.65 140.68 94.79 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 123.237 2.625 . . . . 2.42 113.26 -170.953 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -144.91 -53.41 0.03 OUTLIER Glycine 0 N--CA 1.448 -0.558 0 C-N-CA 120.766 -0.73 . . . . 1.73 112.473 178.866 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 60.1 m80 -97.02 -105.56 0.17 Allowed 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.653 0.263 . . . . 4.3 111.349 -178.495 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.607 ' N ' ' HD ' ' A' ' 11' ' ' HZP . 47.0 t -66.57 -45.53 78.99 Favored 'General case' 0 CA--C 1.538 0.486 0 CA-C-O 119.269 -0.396 . . . . 3.75 111.821 -179.509 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' HZP . . . . . 0.607 ' HD ' ' N ' ' A' ' 10' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 162.37 145.54 4.37 Favored Glycine 0 N--CA 1.444 -0.827 0 C-N-CA 120.855 -0.688 . . . . 2.06 112.433 177.246 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 8.0 p -99.47 -28.43 3.44 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-O 121.387 0.613 . . . . 4.25 109.539 174.829 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -135.66 0.72 3.46 Favored Glycine 0 N--CA 1.448 -0.508 0 CA-C-N 115.498 -0.774 . . . . 3.82 111.789 176.888 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 82.9 t60 . . . . . 0 C--O 1.245 0.832 0 CA-C-O 118.439 -0.791 . . . . 5.31 109.874 179.712 . . . . . . . . 0 0 . 1 stop_ save_